<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risperidone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risperidone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Risperidone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11027" href="/d/html/11027.html" rel="external">see "Risperidone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12770" href="/d/html/12770.html" rel="external">see "Risperidone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709402"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218658"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Perseris;</li>
<li>RisperDAL;</li>
<li>RisperDAL Consta;</li>
<li>Rykindo;</li>
<li>Uzedy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868166"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Risperidone;</li>
<li>APO-Risperidone;</li>
<li>JAMP-Risperidone;</li>
<li>JOI-Risperidone;</li>
<li>Mar-Risperidone;</li>
<li>MINT-Risperidon;</li>
<li>MYLAN-Risperidone ODT [DSC];</li>
<li>Perseris;</li>
<li>PMS-Risperidone;</li>
<li>PRO-Risperidone;</li>
<li>RisperDAL Consta;</li>
<li>RisperDAL [DSC];</li>
<li>RIVA-Risperidone;</li>
<li>SANDOZ Risperidone;</li>
<li>TARO-Risperidone;</li>
<li>TEVA-Risperidone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F218704"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimanic Agent;</li>
<li>
                        Second Generation (Atypical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F218663"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Although manufacturer's labeling includes a maximum dose of up to 16 mg/day, doses &gt;8 mg/day are generally <b>not </b>recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jibson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jibson.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21dde351-f095-4a55-8b49-bf5298b1e8e6">Agitation/Aggression associated with psychiatric disorders, substance intoxication, or other organic causes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia, bipolar disorder), substance intoxication, or other organic causes (alternative agent) (off-label use)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22834451','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22834451','lexi-content-ref-22461918'])">Ref</a></span>). Other agents are used preferentially in some intoxications (eg, stimulants) or alcohol withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.1','lexi-content-ref-26912127','lexi-content-ref-21601409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.1','lexi-content-ref-26912127','lexi-content-ref-21601409'])">Ref</a></span>). Depending on presentation, may combine with a benzodiazepine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 to 2 mg; may repeat every 2 hours to a maximum daily dose of 6 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20523078','lexi-content-ref-Moore.1','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20523078','lexi-content-ref-Moore.1','lexi-content-ref-22461918'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b86ae9af-0983-405b-8c0b-a20590d54c4c">Agitation/Aggression and psychosis associated with dementia, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression and psychosis associated with dementia, severe or refractory (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For short-term use while addressing underlying causes of severe symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>). In patients without a clinically significant response after an adequate trial (eg, up to 4 weeks), taper and withdraw therapy. Only continue in patients with demonstrated benefit; attempt to taper and withdraw at regular intervals (eg, ≤4 months). Patients with dementia with Lewy bodies are at increased risk for severe adverse reactions; caution is required even with low doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 mg/day in 2 divided doses; may increase dose based on response and tolerability in increments of 0.5 mg/day at intervals ≥2 days up to 1 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416','lexi-content-ref-12633121','lexi-content-ref-10084637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416','lexi-content-ref-12633121','lexi-content-ref-10084637'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute mania or acute episodes with mixed features (labeled use) or acute hypomania (off-label use) (monotherapy or adjunctive therapy):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 1 to 3 mg/day in 1 or 2 divided doses; may adjust dose based on response and tolerability in increments of 1 mg/day at intervals ≥24 hours to a usual dose of 4 to 6 mg/day; in general, assess full effect for ≥1 week before further advancing up to 8 mg/day (usual maximum) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-25363101','lexi-content-ref-23238761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-25363101','lexi-content-ref-23238761'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Maintenance treatment (monotherapy or as adjunct to antimanic therapy):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Continue dose and combination regimen that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM ER suspension (alternative route):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Establish tolerability using oral risperidone before first injection. Due to delayed onset of the first ER IM injection, an oral antipsychotic at an effective dose is overlapped for the first 3 weeks.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: 25 mg every 2 weeks; in patients with a history of treatment-refractory illness or requiring high doses of antipsychotics, some experts initiate at 37.5 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20041474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20041474'])">Ref</a></span>). If insufficient response, may increase dose in increments of 12.5 mg no sooner than every 4 weeks to a maximum dose of 50 mg every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20041474','lexi-content-ref-15201572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20041474','lexi-content-ref-15201572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion between oral and IM ER suspension: </i></b>The manufacturer's labeling does not provide dose conversions to IM ER suspension based on current oral dose. Some experts recommend converting to IM ER suspension at the usual starting dose and titrating according to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lauriello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lauriello.1'])">Ref</a></span>). Some experts recommend the following conversions from oral to IM ER suspension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>≤3 mg/day oral</i> = 25 mg IM ER suspension every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>&gt;3 to ≤5 mg/day oral</i> = 37.5 mg IM ER suspension every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>&gt;5 mg/day oral</i> = 50 mg IM ER suspension every 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7092ebe4-ac53-4e80-904b-300a26f7a775">Delusional disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional disorder (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 to 2 mg/day in 1 or 2 divided doses; may increase dose based on response and tolerability in increments of 1 mg/day every 2 weeks; usual dose is ~5 mg/day in 2 divided doses; maximum dose: 8 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24931938','lexi-content-ref-28411574','lexi-content-ref-8599414','lexi-content-ref-Stroup.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24931938','lexi-content-ref-28411574','lexi-content-ref-8599414','lexi-content-ref-Stroup.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7834615-81b5-448d-be0f-b6021963e20a">Delusional infestation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional infestation (delusional parasitosis) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 mg/day in 1 or 2 divided doses; may increase dose based on response and tolerability gradually (ie, weekly) up to 2 to 4 mg/day in 1 or 2 divided doses. Doses up to 8 mg/day may be necessary in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18794644','lexi-content-ref-20465623','lexi-content-ref-Suh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18794644','lexi-content-ref-20465623','lexi-content-ref-Suh.1'])">Ref</a></span>). After achieving adequate response, maintain for at least 1 to 3 months before attempting to taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Suh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Suh.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7100cdf-a3dd-4d7e-8069-adbb4a5c0ba7">Huntington disease–associated chorea, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Huntington disease–associated chorea, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 to 2 mg/day in 1 or 2 divided doses; may increase dose based on response and tolerability in increments of 1 mg/day every week; some patients may require doses up to 10 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10950488','lexi-content-ref-22302895','lexi-content-ref-Suchowersky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10950488','lexi-content-ref-22302895','lexi-content-ref-Suchowersky.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ce6216e-9365-4809-a16e-1401633c5309">Major depressive disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar), treatment resistant (adjunctive therapy with antidepressant) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.25 to 0.5 mg/day; may increase dose based on response and tolerability in increments of 0.25 to 1 mg/day every 3 to 7 days up to 3 mg/day. Usual effective dose: 1 to 1.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18586273','lexi-content-ref-17975181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18586273','lexi-content-ref-17975181'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59e68a42-338e-45a3-bae2-8825f8f2f70d">Obsessive-compulsive disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder, treatment resistant (augmentation to antidepressants) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.25 to 0.5 mg/day; may increase dose based on response and tolerability in increments of 0.5 to 1 mg/day every 3 to 7 days; usual dose: 0.5 to 2 mg/day; doses up to 3 mg/day may be needed for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15572275','lexi-content-ref-10920469','lexi-content-ref-24026523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15572275','lexi-content-ref-10920469','lexi-content-ref-24026523'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 to 2 mg/day in 1 to 2 divided doses; may increase by 1 to 2 mg/day at intervals ≥24 hours to usual dosage range of 2 to 6 mg/day. In general, assess full effect for ≥1 week before further advancing, if needed, to 6 to 8 mg/day (usual maximum). <b>Note:</b> Doses up to 16 mg/day have been evaluated in clinical trials and are approved according to manufacturer's labeling but are associated with increased adverse effects and generally are <b>not </b>recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26338693','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26338693','lexi-content-ref-22834451'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM ER suspension:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Establish tolerability using oral risperidone before first injection. Due to delayed onset of the first IM ER suspension injection, an oral antipsychotic at an effective dose is overlapped for the first 3 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 25 mg every 2 weeks; may increase dose based on response and tolerability in increments of 12.5 to 25 mg every 4 weeks; maximum dose: 50 mg every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Dosage adjustments should not be made more frequently than every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion between oral and IM ER suspension: </i></b>The manufacturer's labeling does not provide dose conversions to IM ER suspension based on current oral dose. Some experts recommend converting to IM ER suspension at the usual starting dose and titrating according to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lauriello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lauriello.1'])">Ref</a></span>). Some experts recommend the following conversions from oral to IM ER suspension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>≤3 mg/day oral</i> = 25 mg IM ER suspension every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>&gt;3 to ≤5 mg/day oral</i> = 37.5 mg IM ER suspension every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>&gt;5 mg/day oral</i> = 50 mg IM ER suspension every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ ER suspension:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Establish tolerability with oral risperidone before starting SUBQ ER suspension injection. Neither a loading dose nor overlap with oral risperidone is needed. Initiate the day after the last dose of oral therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Perseris):</b></p>
<p style="text-indent:-2em;margin-left:8em;">Usual dose: <b>SUBQ</b>: 90 or 120 mg once monthly. Do not administer more than one 90 or 120 mg injection per month.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly or every-2-months injection (Uzedy):</b></p>
<p style="text-indent:-2em;margin-left:8em;">Usual dose: <b>SUBQ:</b> 50 to 125 mg once monthly <b>or</b> 100 to 250 mg every 2 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Conversion between oral and SUBQ ER suspension:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Monthly injection (Perseris):</b></p>
<p style="text-indent:-2em;margin-left:10em;">Oral dose of 3 mg/day is equivalent to SUBQ ER suspension injection of 90 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:10em;">Oral dose of 4 mg/day is equivalent to SUBQ ER suspension injection of 120 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Monthly or every-2-months injection (Uzedy):</b></p>
<p style="text-indent:-2em;margin-left:10em;">Oral dose of 2 mg/day is equivalent to SUBQ ER suspension injection of 50 mg once monthly <b>or </b>100 mg every 2 months.</p>
<p style="text-indent:-2em;margin-left:10em;">Oral dose of 3 mg/day is equivalent to SUBQ ER suspension injection of 75 mg once monthly <b>or </b>150 mg every 2 months.</p>
<p style="text-indent:-4em;margin-left:12em;">Oral dose of 4 mg/day is equivalent to SUBQ ER suspension injection of 100 mg once monthly <b>or </b>200 mg every 2 months.</p>
<p style="text-indent:-2em;margin-left:10em;">Oral dose of 5 mg/day is equivalent to SUBQ ER suspension injection of 125 mg once monthly <b>or </b>250 mg every 2 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Conversion between SUBQ ER suspension Uzedy once monthly and Uzedy every-2-months ER suspension injection</i>:</b> Administer the first dose of the new dosing regimen on the next scheduled date of administration in the original dosing regimen. Then proceed with new dosing schedule.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea2828b9-8d09-48ca-bc5f-04b29b0e7996">Tourette syndrome, management of tics</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, management of tics (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.25 to 0.5 mg/day; may increase gradually based on response and tolerability in increments of ≤1 mg/day every ≥2 days up to 6 mg/day; usual dose: 2.5 to 4 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11235929','lexi-content-ref-11799340','lexi-content-ref-21445724','lexi-content-ref-12682319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11235929','lexi-content-ref-11799340','lexi-content-ref-21445724','lexi-content-ref-12682319'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral: </i>In the treatment of chronic psychiatric disease switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Long-acting injection</i>: Switching to other treatments is generally advised if side effects are intolerable or treatment is not effective. However, if a patient insists on stopping treatment, gradual dose reduction to avoid withdrawal reactions is generally <b>not</b> needed with long-acting injectable antipsychotics. The risk of withdrawal symptoms from discontinuation of long-acting injectables is low because the rate of drug elimination is slow. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching antipsychotics:</b> An optimal universal strategy for switching antipsychotic agents has not been established. Strategies include cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based on clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991246"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Risperidone is extensively hepatically metabolized to 9-hydroxyrisperidone (9-OH-RIS [paliperidone]) (active metabolite) that is mainly excreted by the kidney (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7520903','lexi-content-ref-7507814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7520903','lexi-content-ref-7507814'])">Ref</a></span>). Risperidone and 9-hydroxyrisperidone clearance are decreased by ~60% in patients with CrCl &lt;60 mL/minute/1.73 m<sup>2</sup>, which may increase risk of adverse effects (eg, orthostatic hypotension, QT prolongation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774943','lexi-content-ref-7520903','lexi-content-ref-8748391','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774943','lexi-content-ref-7520903','lexi-content-ref-8748391','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl &gt;60 mL/minute:</i> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl 30 to 60 mL/minute:</i> Initial: Administer 50% to 75% of the usual indication-specific dose; titrate cautiously based on tolerability and response in increments of no more than 0.5 mg twice daily and no more frequently than recommended for patients with normal kidney function; doses &gt;1.5 mg twice daily should be titrated at intervals of ≥1 week. Maximum dose should not exceed 75% of the usual indication-specific dose (expert opinion derived from Gründer 2019; Snoeck 1995; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl 10 to &lt;30 mL/minute:</i> Initial: Administer 50% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774943','lexi-content-ref-8748391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774943','lexi-content-ref-8748391'])">Ref</a></span>). Titrate cautiously in increments of no more than 0.5 mg twice daily and no more frequently than recommended for patients with normal kidney function; doses greater than &gt;1.5 mg twice daily should be titrated at intervals of ≥1 week. Maximum dose should not exceed 50% of the usual indication-specific dose (expert opinion derived from Gründer 2019; Snoeck 1995; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl &lt;10 mL/minute:</i> Consider alternative agent. If necessary, administer 25% of the usual indication-specific dose; titrate cautiously based on tolerability and response in increments of no more than 0.5 mg once daily and no more frequently than recommended for patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM ER suspension:</b> Must establish response and tolerability using oral risperidone before first injection; the manufacturer recommends patients should tolerate an oral dose of at least 2 mg/day before converting to IM ER suspension in patients with impaired kidney function. Due to delayed onset of the first IM ER suspension injection, an oral antipsychotic at an effective dose is overlapped for the first 3 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl &gt;60 mL/minute:</i> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl 10 to ≤60 mL/minute:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Use with caution. Therapeutic drug monitoring and/or careful monitoring for dose-related side effects is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 12.5 to 25 mg every 2 weeks; dose may be increased based on response and tolerability in increments of 12.5 mg no more frequently than every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl &lt;10 mL/minute:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Avoid use (preferred). If necessary, use with caution and closely monitor for adverse effects along with therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 12.5 to 25 mg every 2 weeks; do not exceed 25 mg every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ ER suspension:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Perseris):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CrCl &gt;60 mL/minute:</i> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CrCl 10 to </i>
<i>≤</i>
<i>60 mL/minute:</i> Use with caution (has not been studied); closely monitor for adverse effects along with therapeutic drug monitoring (if available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Use should only be considered in patients able to achieve and tolerate an oral dose of at least 3 mg/day; if tolerated and effective, transition to 90 mg SUBQ ER suspension injection (Perseris) monthly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CrCl &lt;10 mL/minute:</i> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Uzedy):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CrCl &gt;60 mL/minute: </i>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CrCl 10 to ≤60 mL/minute: </i>Use with caution (has not been studied); closely monitor for adverse effects along with therapeutic drug monitoring (if available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Initiate with <b>oral </b>dosing (titrate up to ≥2 mg/day); if tolerated and effective, transition to 50 mg SUBQ ER suspension injection (Uzedy) monthly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b></b>
<i> CrCl &lt;10 mL/minute: </i>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20075665','lexi-content-ref-16175125','lexi-content-ref-31857937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20075665','lexi-content-ref-16175125','lexi-content-ref-31857937'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Use with caution (has not been studied). Dose as for CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Doses up to 2 mg/day have been tolerated in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18655726','lexi-content-ref-16175125','lexi-content-ref-31857937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18655726','lexi-content-ref-16175125','lexi-content-ref-31857937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM ER suspension:</b> Avoid use (preferred). If necessary, use with caution and closely monitor for adverse effects along with therapeutic drug monitoring. After establishing response and tolerability of at least 2 mg oral risperidone, 12.5 to 25 mg every 2 weeks may be initiated with 3 weeks of oral supplementation; do not exceed 25 mg every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ ER suspension: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (high protein binding, moderate V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Use with caution (has not been studied). Dose as in CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM ER suspension:</b> Avoid use (preferred). If necessary, use with caution and closely monitor for adverse effects along with therapeutic drug monitoring. After establishing response and tolerability of at least 2 mg oral risperidone, 12.5 to 25 mg every 2 weeks may be initiated with 3 weeks of oral supplementation; do not exceed 25 mg every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ ER suspension: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Use with caution (has not been studied). Dose as for CrCl 10 to 30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, SUBQ ER suspension:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Use with caution (has not been studied). Dose as for CrCl 10 to 30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, SUBQ ER suspension:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988496"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b>
<b>Note:</b> Limiting initial doses to 1 mg daily (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. The mean free fraction of risperidone in plasma may be increased by 35% in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer’s labeling; reduce dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Initial: 0.5 mg twice daily; titration should progress slowly in increments of no more than 0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should occur at intervals of ≥1 week.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM ER suspension:</b> Initiate with <b>oral</b> dosing (0.5 mg twice daily for 1 week then 1 mg twice daily or 2 mg once daily for 1 week); if tolerated, begin 25 mg IM ER suspension every 2 weeks; continue oral dosing for 3 weeks after the first IM injection. An initial IM dose of 12.5 mg may also be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ ER suspension:</b> Use with caution; has not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Monthly injection (Perseris): </b>Initiate with <b>oral </b>dosing (titrate up to 3 mg/day); if tolerated and effective, transition to 90 mg SUBQ ER suspension injection (Perseris) once monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Monthly injection (Uzedy):</b> Initiate with <b>oral </b>dosing (titrate up to ≥2 mg/day); if tolerated and effective, transition to 50 mg SUBQ ER suspension injection (Uzedy) monthly .</p></div>
<div class="block dot drugH1Div" id="F55642984"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Severe neutropenia (ANC &lt;1,000/mm<sup>3</sup>): Discontinue treatment.</p></div>
<div class="block doe drugH1Div" id="F218664"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose. Of note, use in certain indications may be appropriate (eg, schizophrenia, bipolar disorder) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Dosages in the lower range of recommended adult dosing are generally sufficient with late-onset-schizophrenia or psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10671383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10671383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar mania (<b>monotherapy or as an adjunct to lithium or divalproex)</b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initial: 0.5 mg twice daily; titrate slowly. <b>Note:</b> Limiting initial dose to 1 mg/day (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. Additional monitoring of renal function and orthostatic blood pressure may be warranted.</p>
<p style="text-indent:-2em;margin-left:4em;">IM ER suspension: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initial: 0.5 mg twice daily; titrate slowly. <b>Note:</b> Limiting initial dose to 1 mg/day (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. Additional monitoring of renal function and orthostatic blood pressure may be warranted.</p>
<p style="text-indent:-2em;margin-left:4em;">IM, SUBQ ER suspension: Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F218683"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12770" href="/d/html/12770.html" rel="external">see "Risperidone: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8e14374-cb4f-4862-b44a-cab42469cad1">Bipolar mania</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar mania:</b> Children and Adolescents 10 to 17 years: Oral: Initial: 0.5 mg once daily; dose may be adjusted if needed, in increments of 0.5 to 1 mg/day at intervals ≥24 hours, as tolerated, to a dose of 2.5 mg/day. Doses ranging from 0.5 to 6 mg/day have been evaluated; however, doses &gt;2.5 mg/day do not confer additional benefit and are associated with increased adverse events; doses &gt;6 mg/day have not been studied. <b>Note:</b> May administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily in patients who experience persistent somnolence. In patients ≥11 years, use of long-acting IM risperidone has been described (see "Parenteral therapy").</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="311c8e3c-14be-4190-9b9f-20942524581b">Delirium</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium:</b> Limited data available; optimal dose not established; experience suggests risperidone be considered for hypoactive or mixed delirium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17478595','lexi-content-ref-31093019','lexi-content-ref-17457571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17478595','lexi-content-ref-31093019','lexi-content-ref-17457571'])">Ref</a></span>) dosing should be individualized to response and decreased as soon as appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-28410275','lexi-content-ref-22364403','lexi-content-ref-24898718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-28410275','lexi-content-ref-22364403','lexi-content-ref-24898718'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Very limited data available: Oral: 0.05 to 0.1 mg once daily at bedtime or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23782129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23782129'])">Ref</a></span>). Dosing based on experience with implementation of PICU assessment scales and treatment protocols, small open-label trials which included infants, and case series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-23782129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-23782129'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;5 years: Oral: Initial: 0.1 to 0.2 mg once daily at bedtime; doses may be increased based upon response; dosing based on experience with implementation of PICU assessment scales and treatment protocols, small open-label trials, and expert recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-28410275','lexi-content-ref-22364403','lexi-content-ref-24898718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-28410275','lexi-content-ref-22364403','lexi-content-ref-24898718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral: Initial: 0.2 to 0.5 mg once daily at bedtime; may titrate to lowest effective dose every 1 to 2 days; usual range: 0.2 to 2.5 mg/day in divided doses 2 to 4 times daily; some have suggested maximum daily dose dependent upon patient weight: &lt;20 kg: 1 mg/<b>day</b>; 20 to 45 kg: 2.5 mg/<b>day</b>; &gt;45 kg: 3 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17478595','lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-27924205','lexi-content-ref-20889664','lexi-content-ref-22364403','lexi-content-ref-24898718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17478595','lexi-content-ref-31093019','lexi-content-ref-17457571','lexi-content-ref-27924205','lexi-content-ref-20889664','lexi-content-ref-22364403','lexi-content-ref-24898718'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70841faa-e8e7-441d-a77e-21f59330e672">Disruptive behavior disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Disruptive behavior disorders (eg, conduct disorder [CD], oppositional defiant disorder [ODD]):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A systematic review suggested a high-quality of evidence that risperidone has a moderate effect on disruptive and aggressive behavior in pediatric patients with CD or ODD (with/without attention-deficit/hyperactivity disorder [ADHD]) with average IQ; in ODD or CD pediatric patients (with/without ADHD) with subaverage IQ, a moderate quality of evidence that risperidone has a moderate to large effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25886655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25886655'])">Ref</a></span>). In patients ≥11 years, use of long-acting IM risperidone has been described (see "Parenteral therapy").</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: Oral: Initial: 0.01 mg/kg/dose once daily for 2 days, then 0.02 mg/kg/dose once daily; suggested initial fixed dose in patients &lt;50 kg: 0.25 mg/day, and ≥50 kg: 0.5 mg/day. May further increase on weekly basis as tolerated to 0.06 mg/kg/dose once daily; usual maximum daily dose: 2 mg/<b>day</b>; improvement in target symptoms typically within 1 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12153826','lexi-content-ref-15056514','lexi-content-ref-30702354','lexi-content-ref-14659983','lexi-content-ref-16958564','lexi-content-ref-16513860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12153826','lexi-content-ref-15056514','lexi-content-ref-30702354','lexi-content-ref-14659983','lexi-content-ref-16958564','lexi-content-ref-16513860'])">Ref</a></span>). A large multicenter, double-blind, placebo-controlled trial including 335 patients (n=172 in treatment group; mean age: 10.9 ± 2.93 years) reported that a mean dose of 0.02 mg/kg/day resulted in significant positive changes in efficacy measurements/behavior scales and significantly longer time to symptom recurrence compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16513860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16513860'])">Ref</a></span>). <b>Note:</b> May divide dose and administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily if breakthrough symptoms occur in the afternoon or evening or sedation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ea9a75a-2ad4-41f2-b184-35dd13329aa4">Irritability including aggression, temper, tantrums, self-injurious behavior, and quickly changing moods associated with autism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritability including aggression, temper, tantrums, self-injurious behavior, and quickly changing moods associated with autism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents &lt;18 years: <b>Note:</b> Individualize dose according to patient response and tolerability:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 20 kg: Oral: Initial: 0.25 mg once daily; after ≥4 days, may increase dose to 0.5 mg/day; maintain this dose for ≥14 days. In patients not achieving sufficient clinical response, may increase dose in increments of 0.25 mg/day at ≥2-week intervals. Doses ranging from 0.5 to 3 mg/day have been evaluated; however, therapeutic effect reached plateau at 1 mg/day in clinical trials. Following clinical response, consider gradually decreasing dose to lowest effective dose. May be administered once daily or in divided doses twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: Oral: Initial: 0.5 mg once daily; after ≥4 days, may increase dose to 1 mg/day; maintain this dose for ≥14 days. In patients not achieving sufficient clinical response, may increase dose in increments of 0.5 mg/day at ≥2-week intervals. Doses ranging from 0.5 to 3 mg/day have been evaluated; however, therapeutic effect reached plateau at 2.5 mg/day (3 mg/day in pediatric patients &gt;45 kg) in clinical trials. Following clinical response, consider gradually decreasing to lowest effective dose. May be administered once daily or in divided doses twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b> Adolescents 13 to 17 years: Oral: Initial: 0.5 mg once daily; dose may be adjusted if needed, in increments of 0.5 to 1 mg/day at intervals ≥24 hours, as tolerated, to a dose of 3 mg/day. Doses ranging from 1 to 6 mg/day have been evaluated; however, doses &gt;3 mg/day do not confer additional benefit and are associated with increased adverse events. <b>Note:</b> May administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily in patients who experience persistent somnolence. In patients ≥11 years, use of long-acting IM risperidone has been described (see "Parenteral therapy").</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="661790bb-7a48-479d-9830-aeeb98750c45">Tourette syndrome, tics</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, tics:</b> Limited data available; efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32856174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32856174'])">Ref</a></span>): Compared to placebo, risperidone is probably more likely to reduce tic severity; reserve treatment for situations where benefits outweigh the risks; use lowest effective dose; monitor patients for movement, hormonal and metabolic adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: Oral: Initial: 0.25 to 0.5 mg once daily at night; may gradually titrate every 4 to 5 days in 0.25 to 0.5 mg increments to usual reported therapeutic range: 0.25 to 6 mg/day divided in twice daily doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11799340','lexi-content-ref-21445724','lexi-content-ref-12682319','lexi-content-ref-20848326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11799340','lexi-content-ref-21445724','lexi-content-ref-12682319','lexi-content-ref-20848326'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral therapy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Tolerability with oral risperidone should be established prior to transition to IM risperidone; based on pediatric trials and experience in adult patients, oral risperidone should be continued for 3 weeks after the first IM administration to ensure adequate therapeutic plasma concentrations are reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24171144','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24171144','lexi-content-ref-manu.1'])">Ref</a></span>). Most commonly reported in situations to improve or ensure medication adherence.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-released IM suspension (Risperdal Consta): Children ≥11 years and Adolescents: Maintenance therapy: Usual dose: IM: 25 to 37.5 mg every 2 weeks; dosing dependent on oral risperidone dosing regimen (some patients may require lower initial IM dose of 12.5 mg); titration at intervals of ≥4 weeks to higher doses (eg, 50 mg) may be necessary; most experience is in adolescent patients diagnosed bipolar disorder, schizophrenia, and CD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29397667','lexi-content-ref-24171144','lexi-content-ref-28726075','lexi-content-ref-29381388','lexi-content-ref-30206502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29397667','lexi-content-ref-24171144','lexi-content-ref-28726075','lexi-content-ref-29381388','lexi-content-ref-30206502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation</b>
<b> of therapy:</b> Children and Adolescents: American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451'])">Ref</a></span>); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-16529334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-16529334'])">Ref</a></span>). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Children ≥5 years and Adolescents: Severe neutropenia (ANC &lt;1,000/mm<sup>3</sup>): Discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F51159904"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific dosage recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51159905"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific dosage recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block arsc drugH1Div" id="F54987196"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activating/sedating effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Both activating effects (eg, <b>akathisia, restlessness</b>) and sedating effects (eg, <b>sedated state, drowsiness</b>) may occur with risperidone in all ages and lead to nonadherence or discontinuation. Sedation may result in subsequent <b>falling</b>, particularly in older adults. Individual patient experience can vary depending on the person's sensitivity toward activation or sedation and the dose used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27093218','lexi-content-ref-28141623','lexi-content-ref-18533766','lexi-content-ref-25581312','lexi-content-ref-24003306','lexi-content-ref-23810019','lexi-content-ref-26226481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27093218','lexi-content-ref-28141623','lexi-content-ref-18533766','lexi-content-ref-25581312','lexi-content-ref-24003306','lexi-content-ref-23810019','lexi-content-ref-26226481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27093218','lexi-content-ref-16001094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27093218','lexi-content-ref-16001094'])">Ref</a></span>); sedation is believed to be due to H<sub>1</sub> antagonism leading to potential CNS depressant effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10340682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10340682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Young age (in general, children and adolescents appear to be at higher risk for sedation due to antipsychotics compared to adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>); in studies that included risperidone in children and adolescents, younger age has been associated with activating symptoms and higher age has been associated with sedating symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27093218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27093218'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic (risperidone is generally considered to be mildly sedating at usual therapeutic doses in comparison with other antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16001094','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16001094','lexi-content-ref-30192094'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially life-threatening<b> angioedema </b>has been reported very rarely following oral and IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7488898','lexi-content-ref-23336748','lexi-content-ref-29686794','lexi-content-ref-21112458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7488898','lexi-content-ref-23336748','lexi-content-ref-29686794','lexi-content-ref-21112458'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown but both a nonallergic and allergic mechanism have been proposed, including IgE-related hypersensitivity, kinin-dependent processes, or C<sub>1</sub>-esterase inhibition deficiencies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31534873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31534873'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset following oral therapy has been reported anywhere from &lt;24 hours following a single initial dose to months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26658084','lexi-content-ref-29686794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26658084','lexi-content-ref-29686794'])">Ref</a></span>); onset following parenteral administration usually occurs in the first 48 to 72 hours after injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23336748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23336748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose: Usually occurs after increasing the dose of risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23336748','lexi-content-ref-29686794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23336748','lexi-content-ref-29686794'])">Ref</a></span>), although has also been reported following a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29686794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29686794'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of ritonavir, a weak inhibitor of CYP2D6, may increase risperidone levels leading to cases of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26658084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26658084'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with dyslipidemia in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Although data are inconsistent regarding risperidone’s risk, the following events have been observed: <b>Increased serum cholesterol, decreased HDL cholesterol, </b>and/or<b> increased serum triglycerides </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19364288','lexi-content-ref-19861668','lexi-content-ref-19494785','lexi-content-ref-15869022','lexi-content-ref-21127693','lexi-content-ref-15246458','lexi-content-ref-Morrato.2012','lexi-content-ref-17239039','lexi-content-ref-15998156','lexi-content-ref-17012695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19364288','lexi-content-ref-19861668','lexi-content-ref-19494785','lexi-content-ref-15869022','lexi-content-ref-21127693','lexi-content-ref-15246458','lexi-content-ref-Morrato.2012','lexi-content-ref-17239039','lexi-content-ref-15998156','lexi-content-ref-17012695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747245','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747245','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents may be at increased risk for increased serum triglycerides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19861668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19861668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population primarily due to cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risperidone is usually considered to have a low to intermediate risk for causing lipid abnormalities in adults, although data are inconsistent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-19494785','lexi-content-ref-15869022','lexi-content-ref-15246458','lexi-content-ref-20187598','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-19494785','lexi-content-ref-15869022','lexi-content-ref-15246458','lexi-content-ref-20187598','lexi-content-ref-15998156'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Risperidone is frequently associated with extrapyramidal symptoms (EPS), also known as drug-induced movement disorders. Antipsychotics can cause 4 main EPS: Acute<b> dystonia</b>, drug-induced <b>parkinsonism</b>, <b>akathisia</b>, and <b>tardive dyskinesia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927004','lexi-content-ref-24995318','lexi-content-ref-20187598','lexi-content-ref-28721057','lexi-content-ref-30192094','lexi-content-ref-28867897','lexi-content-ref-21508932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927004','lexi-content-ref-24995318','lexi-content-ref-20187598','lexi-content-ref-28721057','lexi-content-ref-30192094','lexi-content-ref-28867897','lexi-content-ref-21508932'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927004'])">Ref</a></span>). Tardive dyskinesia: Time-related (delayed); results from chronic exposure to dopamine 2 receptor antagonists leading to up-regulation of these receptors over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia:</span> Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (and even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism:</span> Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia:</span> Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia:</span> Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist and almost never before 3 months with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with EPS)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Risperidone is usually associated with a moderate to high propensity to cause EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (Morgenstern 1993), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults &gt;75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia</b>, <b>neutropenia</b>, and <b>thrombocytopenia</b> have been reported rarely with risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29713106','lexi-content-ref-9373440','lexi-content-ref-28794632','lexi-content-ref-28558630','lexi-content-ref-19287562','lexi-content-ref-19134517','lexi-content-ref-29509183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29713106','lexi-content-ref-9373440','lexi-content-ref-28794632','lexi-content-ref-28558630','lexi-content-ref-19287562','lexi-content-ref-19134517','lexi-content-ref-29509183'])">Ref</a></span>). <b>Agranulocytosis </b>has also been reported very rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9619165','lexi-content-ref-11579015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9619165','lexi-content-ref-11579015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unclear and poorly understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28794632','lexi-content-ref-28558630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28794632','lexi-content-ref-28558630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>). In general, drug-induced thrombocytopenia usually occurs 5 to 15 days after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19134517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19134517'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of antipsychotic-induced neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9619165','lexi-content-ref-28558630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9619165','lexi-content-ref-28558630'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia or low white blood cell count/absolute neutrophil count</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with <b>hyperglycemia </b>in adult and pediatric patients, to varying degrees, which is a component of the metabolic syndrome observed with this pharmacologic class. Although data are inconsistent regarding risperidone’s risk, the following events have been observed: <b>Increased serum glucose</b> (fasting) and mild <b>insulin resistance</b> to some cases of new-onset <b>diabetes mellitus</b> and <b>diabetic ketoacidosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-23278567','lexi-content-ref-15610330','lexi-content-ref-11806485','lexi-content-ref-29770221','lexi-content-ref-17239039','lexi-content-ref-15998156','lexi-content-ref-27592232','lexi-content-ref-17604410','lexi-content-ref-28721057','lexi-content-ref-29369497','lexi-content-ref-28636569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-23278567','lexi-content-ref-15610330','lexi-content-ref-11806485','lexi-content-ref-29770221','lexi-content-ref-17239039','lexi-content-ref-15998156','lexi-content-ref-27592232','lexi-content-ref-17604410','lexi-content-ref-28721057','lexi-content-ref-29369497','lexi-content-ref-28636569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23278567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23278567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20520598','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20520598','lexi-content-ref-18348593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (in general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• African American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12046641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12046641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Exposure to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risk of hyperglycemia and/or new onset diabetes appears to be low to moderate with risperidone, although data are inconsistent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-17239039','lexi-content-ref-15998156','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-17239039','lexi-content-ref-15998156','lexi-content-ref-28721057'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperprolactinemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Risperidone commonly causes hyperprolactinemia in adult and pediatric patients, which may lead to <b>gynecomastia, galactorrhea not associated with childbirth, amenorrhea, </b>
<b>sexual disorder</b>, and infertility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21191524','lexi-content-ref-12934975','lexi-content-ref-19958039','lexi-content-ref-19113797','lexi-content-ref-15456328','lexi-content-ref-30106879','lexi-content-ref-20187598','lexi-content-ref-24171143','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21191524','lexi-content-ref-12934975','lexi-content-ref-19958039','lexi-content-ref-19113797','lexi-content-ref-15456328','lexi-content-ref-30106879','lexi-content-ref-20187598','lexi-content-ref-24171143','lexi-content-ref-30192094'])">Ref</a></span>). Although long-term effects of elevated prolactin levels have not been fully evaluated, some studies have also suggested a possible association between hyperprolactinemia and an increased risk for breast and/or pituitary tumors and osteopenia/osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23983962','lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-10718830','lexi-content-ref-16633146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23983962','lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-10718830','lexi-content-ref-16633146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Mechanism: Dose-related and possibly time-related; antagonism of dopamine D<sub>2</sub> receptors in the tuberoinfundibular dopaminergic pathway which causes disinhibition of prolactin release resulting in hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039'])">Ref</a></span>); risperidone has been shown to cause a strong, more prolonged receptor blockade, resulting in a more pronounced and continuous increase in serum prolactin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21191524']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21191524'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset is typically within a few weeks following initiation or dosage increase, but may also arise after long-term stable use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risperidone is considered a prolactin-elevating antipsychotic with a high risk for hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (particularly those of reproductive age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797','lexi-content-ref-19364288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797','lexi-content-ref-19364288'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075'])">Ref</a></span>). In addition, an increased incidence of cerebrovascular effects (eg, <b>cerebrovascular accident</b>, <b>transient ischemic attacks</b>), including fatalities, have been reported in placebo-controlled risperidone trials in older adults with dementia-related psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416','lexi-content-ref-24158020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416','lexi-content-ref-24158020'])">Ref</a></span>). Of note, risperidone is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS), although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with risperidone monotherapy, although most involve concomitant administration of another psychotropic agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12048741','lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-30618887','lexi-content-ref-22854034','lexi-content-ref-18628446','lexi-content-ref-22626633','lexi-content-ref-31071486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12048741','lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-30618887','lexi-content-ref-22854034','lexi-content-ref-18628446','lexi-content-ref-22626633','lexi-content-ref-31071486'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689'])">Ref</a></span>). However, there are many cases of NMS occurring months after stable antipsychotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Additional risk factors for risperidone:</p>
<p style="text-indent:-2em;margin-left:8em;">• Poor metabolizers of CYP2D6 (may be at increased risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18628446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18628446'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Orthostatic hypotension</b> and accompanying <b>dizziness, tachycardia,</b> and<b> syncope </b>may occur, particularly with rapid titration and/or in older adults (which may result in subsequent <b>falling</b> and fracture) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25581312','lexi-content-ref-Gambhir.2014','lexi-content-ref-21790209','lexi-content-ref-20187598','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25581312','lexi-content-ref-Gambhir.2014','lexi-content-ref-21790209','lexi-content-ref-20187598','lexi-content-ref-30192094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Orthostatic hypotension is attributed to alpha-1 receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; per the manufacturer's labeling, orthostatic hypotension is most common during dose initiation, re-initiation, or increase.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Known predisposing conditions (eg, hypovolemia/dehydration)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that also cause or exacerbate orthostatic hypotension (eg, tricyclic antidepressants, antihypertensive medications)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Risperidone has been associated with <b>prolonged QT interval on ECG</b>
<b>, </b>including reports of<b> torsades de pointes </b>(TdP), occurring predominately in patients with other TdP risk factors or receiving concomitant agents that can prolong the QTc interval and/or increase risperidone concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29275963','lexi-content-ref-18030657','lexi-content-ref-26574175','lexi-content-ref-25168784','lexi-content-ref-16096514','lexi-content-ref-15345794','lexi-content-ref-23812796','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29275963','lexi-content-ref-18030657','lexi-content-ref-26574175','lexi-content-ref-25168784','lexi-content-ref-16096514','lexi-content-ref-15345794','lexi-content-ref-23812796','lexi-content-ref-22114630'])">Ref</a></span>). Of the antipsychotics, risperidone is usually associated with a moderate risk for QTc-prolongation (particularly in older patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23295003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23295003'])">Ref</a></span>). In a study in 28 healthy psychiatric patients reaching steady state on risperidone monotherapy (6 to 16 mg/day), the mean change in QTc was 3.6 to 3.9 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14709949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14709949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current, although other mechanisms might also be involved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23812796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23812796'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Additional risk factors for risperidone:</p>
<p style="text-indent:-2em;margin-left:8em;">• Slow CYP2D6 metabolizers or patients taking other drugs that inhibit CYP2D6 (eg, fluoxetine, paroxetine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16096514','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16096514','lexi-content-ref-22114630'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics have been associated with <b>sexual disorders</b> in both males and females. Antipsychotic treatment has been associated with effects on all phases of sexual activity (libido, arousal, and orgasm); however, many patients with schizophrenia experience more frequent sexual dysfunction, with or without antipsychotic treatment. The following adverse reactions have been observed with risperidone: <b>Decreased libido</b>,<b> erectile dysfunction, </b>and<b> abnormal orgasm </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244','lexi-content-ref-20048451','lexi-content-ref-21191308','lexi-content-ref-19264412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244','lexi-content-ref-20048451','lexi-content-ref-21191308','lexi-content-ref-19264412'])">Ref</a></span>). In addition, <b>priapism</b> has been reported with risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26542690','lexi-content-ref-25379316','lexi-content-ref-17366350','lexi-content-ref-23983987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26542690','lexi-content-ref-25379316','lexi-content-ref-17366350','lexi-content-ref-23983987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antipsychotic-induced sexual dysfunction has been attributed to many potential mechanisms, including dopamine receptor antagonism, dopamine D<sub>2 </sub>receptor antagonism in the infundibular dopaminergic pathway causing hyperprolactinemia, histamine receptor antagonism, cholinergic receptor antagonism, and alpha-adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>). Of note, risperidone is associated with a high propensity for hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244','lexi-content-ref-19264412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244','lexi-content-ref-19264412'])">Ref</a></span>). Priapism is believed to be caused by alpha-1 adrenergic antagonism; risperidone has a relatively high affinity for alpha-1 adrenergic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20075651','lexi-content-ref-25379316','lexi-content-ref-17366350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20075651','lexi-content-ref-25379316','lexi-content-ref-17366350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperprolactinemia (although a correlation with sexual dysfunction has been observed, a relationship has not been confirmed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (the prevalence of antipsychotic-induced sexual dysfunction in patients with schizophrenia is high [~50% to 60% compared with 31% of men in the general population]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22533871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22533871'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risperidone is associated with a high prevalence of sexual dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body’s ability to regulate core body temperature, which may cause a potentially life-threatening heat stroke during predisposing conditions, such as heat wave or strenuous exercise. There are also several case reports of potentially life-threatening <b>hypothermia </b>associated with risperidone use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16702902','lexi-content-ref-17698676','lexi-content-ref-24860681','lexi-content-ref-15133539','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16702902','lexi-content-ref-17698676','lexi-content-ref-24860681','lexi-content-ref-15133539','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2A</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, risperidone has pronounced 5-HT<sub>2A</sub> receptor antagonism, with stronger affinity for 5-HT<sub>2A</sub> receptors than for D<sub>2</sub> receptors. In addition, antagonism of peripheral alpha-adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27685194','lexi-content-ref-24688758','lexi-content-ref-15133539','lexi-content-ref-32439747','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27685194','lexi-content-ref-24688758','lexi-content-ref-15133539','lexi-content-ref-32439747','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis benzodiazepine use, alcohol intoxication, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24688758','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24688758','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Risperidone is associated with significant <b>weight gain </b>(increase of ≥7% from baseline) in all ages, which is a component of the metabolic syndrome observed with this pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-19861668','lexi-content-ref-25590213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-19861668','lexi-content-ref-25590213'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-15998156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risperidone is considered to have an intermediate/moderate propensity for causing weight gain; olanzapine and clozapine are associated with a high risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F218624"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperprolactinemia (children and adolescents: 49% to 87%; adults: &lt;4%), weight gain (≥7% kg increase from baseline: 8% to 42%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain')">table 1</a>)</span><span class="table-link" style="display:none;">Weight Gain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain" frame="border" id="lexi-content-weight-gain" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or other psychiatric disorders</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">448</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">375</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">90 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">105</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">90</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">83</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">83</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">158</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">597</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">597</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% gain in body weight</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (5% to 17%), increased appetite (children and adolescents: 4% to 44%; adults: 2% to 4%), nausea (3% to 16%), upper abdominal pain (adolescents: 13% to 16%), vomiting (children and adolescents: 10% to 20%; adults: &lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (children: 16%; adults &lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (≤11%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia table link" class="lexi-table-link" data-table-id="lexi-content-akathisia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia')">table 2</a>)</span><span class="table-link" style="display:none;">Akathisia</span>, anxiety (6% to 16%), dizziness (3% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 3</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drooling (children: 12%; adults: &lt;4%), drowsiness, extrapyramidal reaction (2% to 35%), fatigue (children and adolescents: 18% to 31%; adults: 1% to 9%), headache (12% to 21%), insomnia (adults: 25% to 32%), parkinsonism (6% to 28%)<span class="lexi-table-link-container"> (<a aria-label="Parkinsonism table link" class="lexi-table-link" data-table-id="lexi-content-parkinsonism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-parkinsonism')">table 4</a>)</span><span class="table-link" style="display:none;">Parkinsonism</span>, sedated state, tremor (children and adolescents: 8% to 11%; adults: 2% to 24%; including head titubation)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia" frame="border" id="lexi-content-akathisia" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Akathisia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 2.5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 3 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">448</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">424</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">366</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">90 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">115</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">118</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 2.5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Irritability associated with autistic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">115</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 3 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12.5 to 50 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar I disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">448</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">424</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">366</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Parkinsonism" frame="border" id="lexi-content-parkinsonism" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Parkinsonism</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 2.5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Irritability associated with autistic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">115</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 3 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">448</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">424</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">366</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children: 17%; adults: 2% to 4%), nasopharyngitis (children: 19%; adults: 3% to 4%), rhinorrhea (children: 12%; adults: &lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 16%; adults: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, bundle branch block, chest discomfort, chest pain, ECG changes, first-degree atrioventricular block, hypertension (3%), hypotension, orthostatic dizziness, orthostatic hypotension, palpitations, peripheral edema (≤3%), prolonged QT interval on ECG, syncope (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Syncope table link" class="lexi-table-link" data-table-id="lexi-content-syncope" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-syncope')">table 5</a>)</span><span class="table-link" style="display:none;">Syncope</span>, tachycardia</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Syncope" frame="border" id="lexi-content-syncope" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Syncope</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,499</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,607</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (2%), eczema, pruritus, skin rash (1% to 8%), xeroderma (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (4%), decreased HDL cholesterol, decreased libido, galactorrhea not associated with childbirth, gynecomastia, hyperglycemia, increased serum cholesterol (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-cholesterol')">table 6</a>)</span><span class="table-link" style="display:none;">Increased Serum Cholesterol</span>, increased serum triglycerides (3% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Triglycerides table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-triglycerides" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-triglycerides')">table 7</a>)</span><span class="table-link" style="display:none;">Increased Serum Triglycerides</span>, increased thirst (children: 7%), irregular menses, menstrual disease, menstruation (delayed), weight loss (1% to 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Cholesterol" frame="border" id="lexi-content-increased-serum-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Increased Serum Cholesterol</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or other psychiatric disorders</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">80</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;170 mg/dL to ≥200 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">90 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">109</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥300 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">111</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">109</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥300 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">96</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">368</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">516</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">368</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Triglycerides" frame="border" id="lexi-content-increased-serum-triglycerides" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Increased Serum Triglycerides</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or other psychiatric disorders</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;150 mg/dL to ≥200 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">301</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">180</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;500 mg/dL to ≥500 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">180</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;500 mg/dL to ≥500 mg/dL</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (1% to 3%), abdominal pain, anorexia, decreased appetite (6%), diarrhea (1% to 8%), dyspepsia (3% to 10%), gastritis, gastroenteritis, sialorrhea (1% to 10%), stomach discomfort (2% to 6%), toothache (≤3%), xerostomia (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, delayed ejaculation, erectile dysfunction, glycosuria, infrequent uterine bleeding, mastalgia, sexual disorder, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase, increased liver enzymes, increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, influenza, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, induration at injection site, injection-site reaction, local pain (buttock), localized infection, pain at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (4%), agitation, akinesia, asthenia (1% to 2%), ataxia, depression, disturbance in attention (4%), dysarthria, falling, hypoesthesia (2%), lethargy, malaise, myasthenia, nervousness, pain (1% to 4%), paresthesia, procedural pain, seizure, sleep disturbance, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Abnormal posture, arthralgia (2% to 4%), back pain (1% to 7%), dyskinesia (adults: 6%), dystonia (≤6%)<span class="lexi-table-link-container"> (<a aria-label="Dystonia table link" class="lexi-table-link" data-table-id="lexi-content-dystonia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dystonia')">table 8</a>)</span><span class="table-link" style="display:none;">Dystonia</span>, hypokinesia, increased creatine phosphokinase in blood specimen (1% to 2%), limb pain (≤8%), muscle rigidity (≤3%), muscle spasm (3%), musculoskeletal chest pain, musculoskeletal pain (5%), myalgia, neck pain, tardive dyskinesia</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dystonia" frame="border" id="lexi-content-dystonia" rules="all">
<caption style="text-align:center;">
<b>Risperidone: Adverse Reaction: Dystonia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 to 2.5 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">58</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 3 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 6 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">448</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">424</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 to 16 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 to 8 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">366</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">225</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">118</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">90 mg every 4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ extended-release injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">115</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">118</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (2% to 7%), conjunctivitis, decreased visual acuity</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, otic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, dyspnea, epistaxis (≤2%), flu-like symptoms, nasal congestion (4% to 10%), paranasal sinus congestion (2%), pharyngitis, pharyngolaryngeal pain (3% to 10%), pneumonia, respiratory tract infection (8%), rhinitis (9%), sinusitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cold extremity, flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cheilitis, dermatitis (acarodermatitis), erythema of skin, hyperkeratosis, maculopapular rash, night sweats, onychomycosis, papular rash, seborrhea, seborrheic dermatitis of scalp, skin discoloration, skin lesion</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic coma, hypertriglyceridemia, pituitary neoplasm, polydipsia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bruxism, esophageal motility disorder, fecal incontinence, fecaloma, oral hypoesthesia, tongue paralysis, tongue spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia, breast engorgement, breast hypertrophy, breast secretion, breast tenderness, dysuria, hypomenorrhea, pollakiuria, vaginal discharge</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, granulocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Blunted affect, cerebral ischemia, cerebrovascular accident, cerebrovascular disease, chills, cogwheel rigidity, coma, confusion, impaired consciousness, loss of balance, mask-like face, movement disorder, restlessness, speech disturbance, transient ischemic attacks, trismus, unresponsive to stimuli, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint stiffness, joint swelling, muscle twitching, rhabdomyolysis, torticollis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal eye movements, crusting of eyelid, dry eye syndrome, eye discharge, eye infection, glaucoma, lacrimation, ocular hyperemia, photophobia, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Aspiration pneumonia, bronchopneumonia, hyperventilation, nasal mucosa swelling, rales, respiratory congestion, respiratory distress, tonsillitis, tracheobronchitis, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, deep vein thrombosis (Konnakkaparambil Ramakrishnan 2021), edema (Liu 2020), pulmonary embolism, torsades de pointes (Beach 2018), ventricular tachycardia (Mazhar 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cellulitis, cutaneous nodule, dermal ulcer, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (new onset) (Farwell 2004), diabetic ketoacidosis (Ely 2013), heatstroke (Gomez Ramos 2012), hypoglycemia (Nagamine 2016), increased serum glucose (fasting) (Murashita 2007), insulin resistance (Sukasem 2018), precocious puberty, SIADH (Lee 2015), water intoxication</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, dysphagia (Crouse 2018), intestinal obstruction, oromandibular dystonia (Yoshimura 2016), pancreatitis (Kawabe 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal orgasm (Nagaraj 2009), ejaculation failure (Cichon 2023), priapism (Ateb 2022), retrograde ejaculation (Cichon 2023), urinary retention (Ou 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Finkel 1998), hematoma, leukopenia (Dernovsek 1997), thrombocytopenia (Semba 2009), thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Samra 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Catatonia (Mall 2008, Parraga 2006), hyperthermia, hypothermia (Razaq 2004), mania (Terao 1998), neuroleptic malignant syndrome (Aboraya 2002), somnambulism, stuttering (Sood 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharospasm (Yoshimura 2016), cataract (Balamurugan 2020), intraoperative floppy iris syndrome (with cataract surgery) (Ford 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sleep apnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Tissue necrosis</p></div>
<div class="block coi drugH1Div" id="F218638"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis, angioedema) to risperidone, paliperidone, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F218621"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, risperidone has a low potency of cholinergic blockade (Richelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction or ischemic heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dosage reduction is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal disease; dosage reduction is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dispersible tablet: Inform patients with phenylketonuria that dispersible tablets contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• SUBQ injection site reactions: Following each SUBQ injection, a lump may develop and persist for several weeks; it will decrease in size over time. Do not rub or massage the injection site.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878623"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Long-term usefulness of risperidone should be periodically re-evaluated in patients receiving the drug for extended periods of time. Similar to adult experience, the American Academy of Child and Adolescent Psychiatry (AACAP) guidelines recommend gradually tapering antipsychotics to avoid discontinuation syndrome (withdrawal) symptoms and minimize the risk of relapse (AACAP [McClellan 2007]).</p></div>
<div class="block prod-avail drugH1Div" id="F57811196"><span class="drugH1">Product Availability</span>
<p style="text-indent:-2em;margin-left:2em;">Rykindo (risperidone extended-release injectable suspension): FDA approved January 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Rykindo is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. Consult the prescribing information for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Uzedy: FDA approved April 2023; anticipated availability is unknown. Information pertaining to the product within the monograph is pending revision. Uzedy is an extended-release injectable suspension administered subcutaneously every 1 to 2 months for the treatment of schizophrenia in adults. Consult prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F218631"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Perseris: 90 mg (1 ea); 120 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL: 1 mg/mL (30 mL) [contains benzoic acid]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uzedy: 50 mg/0.14 mL (0.14 mL); 75 mg/0.21 mL (0.21 mL); 100 mg/0.28 mL (0.28 mL); 125 mg/0.35 mL (0.35 mL); 150 mg/0.42 mL (0.42 mL); 200 mg/0.56 mL (0.56 mL); 250 mg/0.7 mL (0.7 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL Consta: 12.5 mg (1 ea); 25 mg (1 ea); 37.5 mg (1 ea); 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg (1 ea); 25 mg (1 ea); 37.5 mg (1 ea); 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rykindo: 25 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rykindo: 25 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rykindo: 37.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rykindo: 37.5 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rykindo: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rykindo: 50 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL: 0.5 mg, 1 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL: 2 mg [contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL: 3 mg [contains corn starch, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL: 4 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p></div>
<div class="block geq drugH1Div" id="F218617"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F218641"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Perseris Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $2,608.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $3,478.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (RisperDAL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $6.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (risperiDONE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $4.87 - $5.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Uzedy Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50MG/0.14ML (per 0.14 mL): $1,537.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75MG/0.21ML (per 0.21 mL): $2,306.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100MG/0.28ML (per 0.28 mL): $3,075.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/0.35ml (per 0.35 mL): $3,843.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150MG/0.42ML (per 0.42 mL): $4,612.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200MG/0.56ML (per 0.56 mL): $6,150.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/0.7 mL (per 0.7 mL): $7,687.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (RisperDAL Consta Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $368.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $737.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $1,106.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,475.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (risperiDONE Microspheres ER Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $350.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $700.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $1,050.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,401.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (Rykindo Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $703.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $1,055.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,407.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (risperiDONE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $4.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $4.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $5.50 - $5.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $8.95 - $9.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $11.29 - $11.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $15.16 - $15.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (RisperDAL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $5.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $5.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $9.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $11.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $15.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (risperiDONE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $3.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $4.27 - $4.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $4.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $7.60 - $7.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $8.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $12.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868167"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Perseris: 90 mg (1 ea); 120 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL: 1 mg/mL ([DSC]) [contains benzoic acid]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (30 mL, 60 mL, 100 mL, 120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RisperDAL Consta: 12.5 mg (1 ea); 25 mg (1 ea); 37.5 mg (1 ea); 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p></div>
<div class="block adm drugH1Div" id="F218635"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution can be administered directly from the provided calibrated oral dose syringe or may be mixed with water, coffee, orange juice, or low-fat milk, but is <b>not compatible</b> with cola or tea.</p>
<p style="text-indent:-2em;margin-left:4em;">Risperdal M-Tab should not be removed from blister pack until administered. Do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds and may be swallowed with or without liquid. Do not split or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM ER suspension:</b> Shake syringe vigorously just before injection. Administer IM into either the deltoid muscle or the upper outer quadrant of the gluteal area. For IM use only; do not administer IV. Avoid inadvertent injection into vasculature. Injection should alternate between the two arms or buttocks. Do not combine two different dosage strengths into one single administration. Do not substitute any components of the dose-pack; administer with needle provided (1-inch needle for deltoid administration or 2-inch needle for gluteal administration). Administer entire contents of the vial to ensure correct dose is provided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ ER suspension:</b> Administer SUBQ ER suspension into the abdomen or back of the upper arm. Choose an injection site with adequate SUBQ tissue that is free of skin conditions (eg, bruising, excessive pigment [including tattoo], infection, tender, callused, hard, irritation, lesions, nodules, redness, scarring or stretch marks).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Monthly injection (Perseris): </b>It is recommended that the patient is in the supine position. Rotate injection sites. When product reaches room temperature for ≥15 minutes, administer with 18G x 5/8" safety needle provided. There may be a lump at the injection site for several weeks; this will decrease in size over time. Do not rub injection site; be aware of the placement of any belts, waistbands, sleeves, cuffs, or other clothing parts. Refer to manufacturer’s labeling for product-specific detail.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Monthly or every-2-months injection (Uzedy): </b>Do not substitute any components of the dose pack; when product reaches room temperature for ≥30 minutes, administer with 21G x 5/8” needle provided. Resistance will be experienced during administration; do not use excessive force in an attempt to deliver medication faster. Refer to manufacturer’s labeling for product-specific detail.</p></div>
<div class="block admp drugH1Div" id="F52613823"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: May administer directly from the manufacturer provided calibrated oral syringe or may mix with water, coffee, orange juice, or low-fat milk; do not mix with cola or tea.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablets: Do not remove tablet from blister pack until ready to administer; do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue; tablet will dissolve within seconds and may be swallowed with or without liquid; do not split or chew tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Extended-release suspension (Risperdal Consta): IM: Children ≥11 years and Adolescents: For IM injection by a health care provider; do not administer IV. Shake syringe vigorously just before injection. Administer IM into either the deltoid muscle (using a 1-inch needle) or the upper outer quadrant of the gluteal area (using a 2-inch needed). Avoid inadvertent injection into vasculature. Injection should alternate between sides of the body. Do not combine 2 different dosage strengths into 1 single administration or use a different syringe other than the one provided to administer a partial dose. Do not substitute any components of the dose-pack. Administer entire contents of the vial to ensure correct dose is provided. For single use only; discard vial and vial adapter after use.</p></div>
<div class="block use drugH1Div" id="F218634"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Long-acting IM injection:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bipolar disorder:</b> As monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Schizophrenia:</b> Treatment of schizophrenia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Oral:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bipolar mania:</b> As monotherapy or as adjunctive therapy to lithium or valproate for the treatment of acute mania or acute episodes with mixed features associated with bipolar disorder in adults or as monotherapy for the treatment of acute mania or acute episodes with mixed features associated with bipolar disorder in children and adolescents 10 to 17 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Irritability associated with autistic disorder:</b> Treatment of irritability associated with autistic disorder in children and adolescents 5 to 17 years of age, including symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Schizophrenia: </b>Treatment of schizophrenia in adults and adolescents 13 to 17 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Subcutaneous injection:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Schizophrenia:</b> Treatment of schizophrenia in adults.</p></div>
<div class="block off-label drugH1Div" id="F25744895"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia, bipolar disorder), substance intoxication, or other organic causes; Agitation/Aggression and psychosis associated with dementia, severe or refractory; Bipolar disorder, hypomania; Delusional disorder; Delusional infestation (delusional parasitosis); Huntington disease–associated chorea; Major depressive disorder (unipolar), treatment resistant; Obsessive-compulsive disorder, treatment resistant; Tourette syndrome</p></div>
<div class="block mst drugH1Div" id="F218713"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">RisperiDONE may be confused with reserpine, rOPINIRole</p>
<p style="text-indent:-2em;margin-left:4em;">RisperDAL may be confused with lisinopril, reserpine, Restoril, rOPINIRole</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for FDA approved indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F218697"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major), CYP3A4 (major), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F218625"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: May enhance the QTc-prolonging effect of RisperiDONE. Adagrasib may increase the serum concentration of RisperiDONE. Management: Consider alternatives to this combination. If combined, monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Armodafinil: May decrease serum concentrations of the active metabolite(s) of RisperiDONE. Armodafinil may decrease the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the QTc-prolonging effect of RisperiDONE. Azithromycin (Systemic) may increase the serum concentration of RisperiDONE. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: RisperiDONE may enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of RisperiDONE.  Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of ClomiPRAMINE. QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of ClomiPRAMINE. This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of RisperiDONE. Management: Careful monitoring for risperidone toxicities and possible dose adjustment are recommended when combined with strong CYP2D6 inhibitors. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE. Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with strong CYP3A4 inducers. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of RisperiDONE. Dabrafenib may decrease the serum concentration of RisperiDONE. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced risperidone efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: RisperiDONE may enhance the QTc-prolonging effect of Encorafenib. Encorafenib may decrease the serum concentration of RisperiDONE.  Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with encorafenib. Additionally, monitor for increased QTc interval prolongation and arrhythmias. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): RisperiDONE may enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may increase the serum concentration of RisperiDONE.  Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Flupentixol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of Imipramine. This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the adverse/toxic effect of RisperiDONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: RisperiDONE may enhance the adverse/toxic effect of Paliperidone.  Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of RisperiDONE. Propafenone may increase the serum concentration of RisperiDONE. Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Propofol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of RisperiDONE. QT-prolonging Antipsychotics (Moderate Risk) may increase the serum concentration of RisperiDONE. Specifically, thioridazine may increase concentrations of risperidone. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): RisperiDONE may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of RisperiDONE. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of RisperiDONE. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QUEtiapine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the QTc-prolonging effect of RisperiDONE. QuiNIDine may increase the serum concentration of RisperiDONE. Management: Consider alternatives to this drug combination. If combined, monitor for risperidone toxicities, including QTc interval prolongation and TdP. Risperidone dose adjustment may also be needed. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): May enhance the QTc-prolonging effect of QT-prolonging CYP2D6 Substrates. Quinidine (Non-Therapeutic) may increase the serum concentration of QT-prolonging CYP2D6 Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Saquinavir.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: RisperiDONE may enhance the QTc-prolonging effect of Vemurafenib. Vemurafenib may increase the serum concentration of RisperiDONE.  Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F218655"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Oral solution is not compatible with beverages containing tannin or pectinate (cola or tea). Management: Administer oral solution with water, coffee, orange juice, or low-fat milk.</p></div>
<div class="block rep_considerations drugH1Div" id="F53575796"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Risperidone may cause hyperprolactinemia, which may cause a reversible decrease in reproductive function in females.</p>
<p style="text-indent:0em;margin-top:2em;">If treatment with an atypical antipsychotic is needed in a woman planning a pregnancy, use of an agent other than risperidone is preferred (Larsen 2015). When using the IM injection, patients should notify health care provider if they intend to become pregnant during therapy or within 12 weeks of last injection.</p></div>
<div class="block pri drugH1Div" id="F2888768"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Risperidone and its metabolite cross the placenta (Newport 2007). Agenesis of the corpus callosum has been noted in one case report of an infant exposed to risperidone in utero; relationship to risperidone exposure is not known. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">When using the IM injection, patients should notify health care provider if they become pregnant during therapy or within 12 weeks of last injection.</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited. As a result, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is initiated during pregnancy, use of an agent other than risperidone is preferred (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to risperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://womensmentalhealth.org/research/pregnancyregistry/).</p></div>
<div class="block brc drugH1Div" id="F218642"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Risperidone and its active metabolite, 9-hydroxyrisperidone, are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of risperidone is 1.5% and the RID of 9-hydroxyrisperidone is 5.5% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 2 mg/day. Per the manufacturer, the RID for risperidone and the metabolite range between 2.3% and 4.7% of the weight-adjusted maternal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of risperidone was calculated using a milk concentration of 3 ng/mL, providing an estimated daily infant dose via breast milk of 0.45 mcg/kg/day. The RID of 9-hydroxyrisperidone was calculated using a milk concentration of 11 ng/mL, providing an estimated daily infant dose via breast milk of 1.65 mcg/kg/day. These milk concentrations were obtained following maternal administration of oral risperidone 2 mg/day, with sampling occurring 3 hours after the maternal dose following 6 days of therapy; treatment started 1 week postpartum (Aichhorn 2005). Peak milk concentrations appear to be within 2 to 4 hours after an oral maternal dose (Aichhorn 2005; Hill 2000; Ilett 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, infants exposed to second generation antipsychotics via breast milk should be monitored weekly for the first month of exposure for symptoms, such as appetite changes, insomnia, irritability, or lethargy (Uguz 2016). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Based on available information, use of agents other than risperidone in breastfeeding women is preferred (Larsen 2015; Pacchiarotti 2016; Uguz 2016).</p></div>
<div class="block dic drugH1Div" id="F218643"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be taken without regard to meals. Dispersible tablets contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F218629"><span class="drugH1">Monitoring Parameters</span>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Frequency of Antipsychotic Monitoring<sup>a,b</sup></b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Monitoring parameter</p></th>
<th align="center">
<p style="text-indent:0em;">Frequency of monitoring</p></th>
<th align="center">
<p style="text-indent:0em;">Comments</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>For all monitoring parameters, it is appropriate for check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> ADA 2004; APA [Keepers 2020]; De Hert 2011; Gugger 2011; manufacturer's labeling.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Risk factors for tardive dyskinesia include age &gt;55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or CNS injury; and past or current EPS.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adherence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Blood chemistries (electrolytes, renal function, liver function, TSH)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">CBC</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">As clinically indicated</p></td>
<td align="center">
<p style="text-indent:0em;">Check frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extrapyramidal symptoms</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>c</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fall risk</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fasting plasma glucose/HbA<sub>1c</sub></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">12 weeks after initiation and dose change; annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check more frequently than annually if abnormal. Follow diabetes guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lipid panel</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">12 weeks after initiation and dose change; annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check more frequently than annually if abnormal. Follow lipid guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mental status and alertness</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Metabolic syndrome history</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prolactin</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hyperprolactinemia symptoms: Changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tardive dyskinesia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>d</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Vital signs (BP, orthostatics, temperature, pulse, signs of infection)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change.</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Weight/Height/BMI</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">8 and 12 weeks after initiation and dose change; quarterly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome.</p>
<p style="text-indent:0em;text-align:left;">Consider changing antipsychotic if BMI increases by ≥1 unit.</p>
<p style="text-indent:0em;text-align:left;">Some experts recommend checking weight and height at every visit.</p></td></tr></tbody></table></div>
<div class="block rer drugH1Div" id="F55469116"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Risperidone plus 9-hydroxy-risperidone:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum samples: Draw trough just before next dose (Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic reference range: 20 to 60 ng/mL (SI: 48.8 to 146.4 nmol/L) (Hiemke 2018). <b>Note:</b> Dosing should be based on therapeutic response as opposed to serum concentrations; however, therapeutic drug monitoring can be used to confirm adherence (APA [Keepers 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Laboratory alert level: 120 ng/mL (SI: 292.8 nmol/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F218620"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Risperidone is a benzisoxazole atypical antipsychotic with high 5-HT<sub>2 </sub>and dopamine-D<sub>2</sub> receptor antagonist activity. Alpha<sub>1</sub>, alpha<sub>2</sub> adrenergic, and histaminergic receptors are also antagonized with high affinity. Risperidone has low to moderate affinity for 5-HT<sub>1C</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>1A</sub> receptors, weak affinity for D<sub>1</sub> and no affinity for muscarinics or beta<sub>1</sub> and beta<sub>2</sub> receptors.</p></div>
<div class="block phk drugH1Div" id="F218637"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Following oral administration, the pharmacokinetics of risperidone and 9-hydroxyrisperidone in children were found to be similar to values in adults (after adjusting for differences in body weight).</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Agitation: Orally disintegrating tablet: Median time to calm: 70 minutes (Normann 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Oral: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Major depressive disorder, unipolar: Oral: Initial effects may be observed within 1 week with continued improvements over 6 to 12 weeks (Wen 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Rapid and well absorbed; food does not affect rate or extent.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: &lt;1% absorbed initially; main release occurs at ~3 weeks and is maintained from 4 to 6 weeks; release ends by 7 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Perseris): </b>Two absorption peaks; first release occurs immediately after injection and second release occurs around 10 to 14 days; therapeutic levels maintained for 4 weeks after injection.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly or every-2-months injection (Uzedy): </b>Two absorption peaks, one resulting in therapeutic concentrations within 6 to 24 hours, followed by a second peak around 8 to 14 days; therapeutic levels maintained for 28 or 56 days after injection, depending on dose (Perlstein 2022; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1 to 2 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: Risperidone 90%; 9-hydroxyrisperidone: 77%; <b>Note: </b>Risperidone free fraction may be increased by ~35% in patients with hepatic impairment due to decreased concentrations of albumin and alpha-1 acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP2D6 to 9-hydroxyrisperidone (similar pharmacological activity as risperidone); <i>N</i>-dealkylation is a second minor pathway; <b>Note:</b> 9-hydroxyrisperidone is the predominant circulating form and is approximately equal to risperidone in receptor binding activity; clinical effects are from combined concentrations of risperidone and 9-hydroxyrisperidone; clinically important differences between CYP2D6 poor and extensive metabolizers are not expected (pharmacokinetics of the sum of risperidone and 9-hydroxyrisperidone were similar in poor and extensive metabolizers).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 70%; Tablet (relative to solution): 94%; orally-disintegrating tablets and oral solution are bioequivalent to tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Deltoid IM injection is bioequivalent to gluteal IM injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Active moiety (risperidone and its active metabolite 9-hydroxyrisperidone):</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 20 hours (mean); prolonged in elderly patients.</p>
<p style="text-indent:-2em;margin-left:8em;">Extensive metabolizers: Risperidone: 3 hours; 9-hydroxyrisperidone: 21 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Poor metabolizers: Risperidone: 20 hours; 9-hydroxyrisperidone: 30 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 3 to 6 days; related to microsphere erosion and subsequent absorption of risperidone.</p>
<p style="text-indent:-2em;margin-left:4em;">Risperidone: SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Perseris): </b>9 to 11 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly or every-2-months injection (Uzedy)</b>: 14 to 22 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Risperidone: Within 1 hour; 9-hydroxyrisperidone: Extensive metabolizers: 3 hours; Poor metabolizers: 17 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Perseris): </b>Risperidone: First peak: 4 to 6 hours; Second peak: 10 to 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly or every-2-months injection (Uzedy):</b> Risperidone and 9-hydroxyrisperidone: First peak: Results in therapeutic concentrations within 6 to 24 hours; Second peak: 8 to 14 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70%; primarily as active metabolite); feces (14%) (Mannens 1993).</p></div>
<div class="block phksp drugH1Div" id="F51159793"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: CrCl 10 to 60 mL/minute: Clearance of parent drug and active metabolite decreased ~60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Mean free fraction of risperidone in plasma increased approximately 35%.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Oral: Renal clearance of parent drug and active metabolite was decreased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218644"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperdal consta | Rispitab</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Altexina | Dozic | Dropicine | Dropicine flash | Restelea | Riatul | Risperdal | Risperdal consta | Risperidona dosa | Risperidona fabra | Risperin | Rispex | Roxodyn | Sequinan | Seroxina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aleptan | Okedi | Risperdal | Risperdal consta | Risperidon | Risperidon +Pharma | Risperidon 1A Pharma | Risperidon actavis | Risperidon Alternova | Risperidon genericon | Risperidon hexal | Risperidon Pfizer | Risperidon ratiopharm | Risperidon sandoz | Risperidon stada | Risperidone Ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo risperidone | Noumed risperidone | Ozidal | Resdone | Rispa | Risperdal | Risperidone actavis | Risperidone an | Risperidone Generic Health | Risperidone generichealth | Risperidone pfizer | Risperidone sandoz | Risperidone-GA | Rispernia | Rixadone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Frenia | Resco | Riscord | Risdon | Rispa | Risperdal consta | Risperdex | Rispolux | Sizodon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperidone accord | Risperidone eg | Risperidone Ratiopharm | Risperidone sandoz | Risperidone teva | Risperimylan | Risperiphar | Rispimedica</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Medorisper | Neorisp | Resperon | Risperdal | Rispolept | Rispolept consta | Rispolux | Rissar | Ronydal | Speridan | Torendo | Torendo q</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Esquidon | Perlid | Respidon | Ripevil | Risleptic | Rispalum | Risperdal | Risperidon | Risperidona | Risperix | Riss | Viverdal | Zargus</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperdal consta | Risperidon actavis | Risperidon Helvepharm | Risperidon Mepha | Risperidon sandoz | Risperidon Spirig | Risperidon Streuli | Risperidon teva | Risperidon zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Respal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dagotil | Goval | Radigen | Rimox | Risperdal | Spiron ft</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Chan ke | Jing ping | Ke tong | Risperdal | Risperdal consta | Suo le | Wei si tong | Zhuo fei | Zhuo fu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Isperin | Peridon | Risdona | Risnia | Risofren | Risperdal | Risperdal consta | Risperidona | Risperidona mk | Risperimed | Rispolux | Sicopidol | Spiron | Tractal | Uni senidrin | Zyrisp</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Risper | Medorisper | Rileptid | Risepro | Rispen | Rispera | Risperdal | Risperdal consta | Risperidon farmax | Risperidon orion | Risperidon ratiopharm | Risperidon Vipharm | Rispolux | Risset | Rorendo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Belivon | Okedi | Rehablit | Risocon | Rispe Q | Rispecare | Risperdal | Risperdal consta | Risperdoc | Risperid Heumann | Risperidon | Risperidon 1 A Pharma | Risperidon AAA | Risperidon Accord | Risperidon Acis | Risperidon actavis | Risperidon AL | Risperidon Aristo | Risperidon Atid | Risperidon aurobindo | Risperidon Aurus | Risperidon basics | Risperidon Beta | Risperidon Biomo | Risperidon CT | Risperidon devatis | Risperidon Esparma | Risperidon Hennig | Risperidon Heumann | Risperidon hexal | Risperidon Hormosan | Risperidon kohne pharma | Risperidon mylan | Risperidon Neuraxpharm | Risperidon Pfizer | Risperidon puren | Risperidon ratiopharm | Risperidon Real | Risperidon sandoz | Risperidon stada | Risperidon teva | Risperidon Volkspharma | Risperidon Winthrop | Risperidone Biomo | Risperigamma | Rispolept | Rispolept consta</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Risperanne</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Avanxe | Evolux | Goval | Peridona | Rempil | Ridona | Ripexil | Risdon | Risdoril | Risperdal | Risperdal consta | Risperidona | Risperidona mamey | Risperin | Uniridona | Xicoretic</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Goval | Risperdal | Risperdal consta | Risperidona | Risperoxial | Rispolux | Spiron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Medorisper | Rispen | Risperidone accord | Rispolept | Rispolept consta | Risset</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apexidone | Itorisperidone | Psychodal | Riscure | Risdal | Risidrone | Rispadex | Risperdal | Schizodal | Sigmadone | Zesperone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arketin | Calmapride | Diaforin | Okedi | Risperdal | Risperdal consta | Risperdal flas | Risperidona Actavis | Risperidona alter | Risperidona Aphar | Risperidona apotex | Risperidona aristo | Risperidona Asol | Risperidona Aurobindo | Risperidona aurovitas | Risperidona bayvit | Risperidona Bexal | Risperidona cinfa | Risperidona curaxys | Risperidona davur | Risperidona edigen | Risperidona farmalider | Risperidona kern pharma | Risperidona krka | Risperidona Mabo | Risperidona Mylan | Risperidona mylan pharmaceuticals | Risperidona Normon | Risperidona Pharmacia | Risperidona Qualigen | Risperidona ranbaxy | Risperidona Ratiopharm | Risperidona Sandoz | Risperidona Stada | Risperidona Sumol | Risperidona tarbis | Risperidona Tecnigen | Risperidona teva | Risperidona tevagen | Risperidona ur | Risperidona winthrop</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Risdone | Rispharm | Rispons</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rismyl | Rispazin | Risperdal | Risperdal consta | Risperidon actavis | Risperidon bmm pharma | Risperidon hexal | Risperidon krka | Risperidon orion | Risperidon Pfizer | Risperidon ratiopharm | Risperidon sandoz | Risperidon teva | Risperidone Stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperdalconsta lp | Risperdaloro | Risperidone actavis | Risperidone Almus | Risperidone alter | Risperidone Arrow | Risperidone biogaran | Risperidone cristers | Risperidone eg | Risperidone evolugen | Risperidone Mylan | Risperidone Panpharma | Risperidone Qualimed | Risperidone Qualimed Generiques | Risperidone Ranbaxy | Risperidone Ratiopharm | Risperidone sandoz | Risperidone teva | Risperidone Wyvern medical | Risperidone Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Okedi | Risperdal | Risperdal consta | Risperidone Kent | Risperidone sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adovia | Axelabron | Belasperdal S | Capulton | Depolan | Deteron | Dixine | Helposper | Isipredon | Lassen | Linipon | Lucipral | Natibo | Novoris | Orotral | Psychordal | Ribex | Ridoron | Rifocus | Ripepral | Risenar | Risgal | Risidral | Rispalm | Rispefar | Rispelen | Rispen | Risperascol | Risperdal | Risperdal consta | Risperidone/generics | Risperidone/Teva | Risperom | Risperoprol | Rispersan | Rubrum | Sperelax | Wisperdon | Zafitral</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo risperidone | Pms risperidone | Rison | Risperdal | Risperdal consta</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Prospera | Risdonal | Risnia | Rispen | Risperidon Pliva | Rispolept | Rispolept consta | Rispolux | Risset</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hunperdal | Perdox | Rileptid | Ripedon | Rispe | Risperdal | Risperdal consta | Risperidon orion | Risperidon ratiopharm | Risperidone teva | Risperwin | Rosipin | Ziperid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Neripros | Nodiril | Noprenia | Persidal | Risperdal | Risperdal consta | Rizodal | Zofredal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Perdamel | Rispal | Risperdal | Risperdal consta | Risperger | Rispeva | Rispone | Sperizak</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperdal consta | Risperidex | Rispond</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alrison | Don | Eauris | Genrest | Halodone | Peridon | Psydon | Psyorid | Regrace | Repadone | Respidon | Respimed | Resque | Restek | Restonorm | Ridon | Rinext | Rion | Ris | Riscalm | Riscon | Riscure | Risdone | Risgold md | Risnia | Risp | Risperdal | Rispid | Rispond | Ristab | Riswel | Rozidal | Rpdone | Rythem | Sizodon | Sizodon md | Sizomax | Sycodone | Zepid | Zisper</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Ripredon | Risperodel | Rispersaf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperidone actavis | Risperidone AHCL | Risperidone alter | Risperidone Arrow | Risperidone aurobindo | Risperidone dr reddy's | Risperidone Mylan | Risperidone Ranbaxy | Risperidone Ratiopharm</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Raxidone | Respal | Respirox | Ribex | Risdone | Risperdal | Risperdal consta | Rispharm</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperidone Amel | Risperidone kunihiro | Risperidone meek | Risperidone sawai | Risperidone Towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Masrone | Respidon | Risdone | Risna | Risobon | Risperdal | Rispons | Sizodon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">I peridone | Iperidone | Myungmoon risperidone | New ripedone | Pms risperidone | Riopedone | Ripedine | Ripedone | Riperidon | Riperil | Risdal | Risdon | Risdone | Risoperin | Rispedone | Rispeldon | Rispen | Risperdal | Risperdal consta | Risperin | Rispidon | Rispodon | Rispri | Samsung risperidone | Spendalin | Uniperidone | Weridone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ribex | Ridon | Risdone | Risperdal | Risperdal consta | Rispons</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Depia | Lucipral | Pms risperidone | Raxidone | Razvan | Respirox | Rischotic | Rispefar | Risperdal | Risperdal consta | Risperidone biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aleptolan | Medorisper | Rileptid | Rispaxol | Rispen | Risperdal | Risperidone teva | Rispolept | Rispolept consta | Risset | Torendo q</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperidon mylan | Risperidone eg | Risperidone jc | Risperidone Ratiopharm | Risperidone sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aleptolan | Medorisper | Risperdal | Risperidone accord | Risperidone teva | Rispolept | Rispolept consta</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Isperid | Prisdal | Risperdal | Risperidone gt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kronoax | Limbik | Lost Per | Norispez | Reskizof | Risotor | Risperdal | Risperdal consta | Risperdal quicklet | Risperidona | Rispolux | Silderec | Tipedsina | Upmotev | Zenodone | Zesperone</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo risperidone | Intasrisdone | Resicalm | Respidon | Risperdal | Risperdal consta | Risperone | Rozidal | Zesperone MD</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Milton risperidone | Milzocate | Risdal | Risper | Risperidone sandoz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Okedi | Risperdal | Risperdon | Risperidon | Risperidon Accord | Risperidon sandoz | Risperidon teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperdal consta | Risperidon | Risperidon actavis | Risperidon krka | Risperidon sandoz | Risperidon stada | Rispolept consta</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo risperidone | Drreddys risperidone | Noumed risperidone | Ridal | Risperdal | Risperidone actavis | Risperidone dr reddy | Risperon</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Denoral | Risperdal | Risperidona | Risperite | Rozidal | Sizodon | Zeclonex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aspidon | Renuvie | Reone | Residon | Respixl | Ridonex | Rileptid | Riscare | Risdin | Risdin ODT | Risdoplus | Risgen | Rispedin | Rispen | Risperdal | Risperdal consta | Risperidone consta | Rispolux | Rispond | Risponz | Ritemed risperidone | Sizodon | Steviso | Zysda</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Apprid | Arsodon | Bedone | Benzisox | Biodin | Bioris | Bris | Buzon | Devidone | Donresp | Espidone | Fleelax | Isrip | Lirc | Mozart | Mytodone | Neo risp | Neoris | Novril | Oridone | Oris | Peridal | Persch | Persept | Primed | Psyper | Raze | Recept | Remet | Resigrin | Resimon | Resjun 1 | Resjun 2 | Resperose | Respimed | Respivant | Reves | Revoc | Rezcalm | Ridal | Riscalm | Riscare | Risdopa | Risha | Rislet | Risp | Risperdal | Risperiscot | Rispinol | Rispolet | Risricot | Riss | Riswrd | Risynth | Sai rest | Sperid | Sycocar | Sycon | Sycorest | Vepridone | Wake up | Wenoris | Wizen | Zargus | Zedone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo Risperid | Doresol | Galperinon | Lioxam | Mepharis | Nodir | Orizon | Ranperidon | Rileptid | Rispen | Risperatio | Risperdal | Risperdal consta | Risperidon Vipharm | Risperidone Bmm Pharma | Risperidone farmax | Risperiwin | Risperon | Rispofren | Rispolept | Rispolux | Risset | Ryspolit | Speridan | Torendo q | Ziperid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Perseris | Risperdal | Risperdal consta</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Azirosama | Doprifane | Okedi | Perdin | Risperdal | Risperdal consta | Risperidona accord | Risperidona Aurobindo | Risperidona Baldacci | Risperidona ciclum | Risperidona Decafarma | Risperidona Dhira | Risperidona generis | Risperidona Germed | Risperidona Ratiopharm | Risperidona Sandoz | Risperidona wynn | Risperidone Mylan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Levo prom | Risperdal | Risperidona whelp | Risperix | Rsp</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Raxidone | Respal | Ridon | Risperdal | Risperdal Consta | Rispons</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Essens | Essens OD | Rison | Risperidone teva | Rispolept consta | Rispolux | Torendo | Xenoma</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Leptinorm | Rezalen | Ridonex | Rilept | Risdonal | Rispaksole | Rispaxol | Rispen | Risperidone krka | Risperidone Organika | Risperidone tl | Rispolept | Rispolept consta | Rispolept quicklet | Rispolux | Risset | Torendo | Torendo q | Torendo q tab</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo risperidone | Calmtrol | Pms risperidone | Respal | Ridon | Risidone | Risperdal | Risperdal consta | Rispitab | Saxid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abriact | Rispemyl | Risperdal | Risperdal consta | Risperidon | Risperidon abacus medicine | Risperidon actavis | Risperidon arrow | Risperidon bluefish | Risperidon bmm pharma | Risperidon copyfarm | Risperidon ebb | Risperidon krka | Risperidon medartuum | Risperidon mylan | Risperidon orifarm | Risperidon orion | Risperidon ratiopharm | Risperidon sandoz | Risperidon stada | Risperidon teva | Risperidone teva gmbh | Rispolept consta</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo risperidone | Eperon | Ridkline | Risperdal | Risperdal consta | Risperidex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Risperdal | Risperdal consta | Risperidon Alkaloid | Risperidon teva | Rispolux | Rispons | Risset | Torendo</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Medorisper | Rispen | Risperdal | Risperdal consta | Risperidon | Risperidon +Pharma | Risperidon farmax | Risperidon orion | Risperidon sandoz | Risperidon teva | Rispolux | Risset | Torendo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Neuris | Risdal | Rispel | Risperdal | Risperdal consta | Risperidone GPO</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Raxidone | Respirox | Risdone | Risperdal | Risperdalconsta lp | Risperidone teriak</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Perilife | Restela | Ricus | Ripesil | Riplidon | Risperdal | Risperdal consta | Rixol | Rixper</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anxilet | Apo risperidone | Blue Up | Perisdone | Respor | Riper | Risdal | Risdon | Risdone | Risperdal | Risperdal consta | Spiterin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Eridon | Rispaxol | Rispen | Risperidon apo | Risperidon sandoz | Risperon | Rispetril | Rispolept | Rispolept quicklet | Rispon | Risset | Rosemide | Rosemide odt | Rostalept rota | Sizodon | Torendo</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Respiwel | Risdone | Rispitas</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Goval | Narval 3 | Restelea | Risperdal | Risperidona | Risperix | Rsp</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ridal | Ripevil | Risperdal | Risperid | Risperidona | Rispolux</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agirisdon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen risperidone | Auroperdal | Auropidone | Drl Risperidone | Perida | Perizal | Risnia | Rispacor | Risperdal | Risperidone Hexal | Risperidone Mylan | Risperlet | Rispevon | Rispide | Risponz | Rutra | Schizorol | Zoxadon | Zoxadon odt</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Risdone</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Risperdal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21191524">
<a name="21191524"></a>Aboraya A, Fullen JE, Ponieman BL, Makela EH, Latocha M. Hyperprolactinemia associated with risperidone: a case report and review of literature. <i>Psychiatry (Edgmont)</i>. 2004;1(3):29-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21191524/pubmed" id="21191524" target="_blank">21191524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12048741">
<a name="12048741"></a>Aboraya A, Schumacher J, Abdalla E, et al. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. <i>W V Med J</i>. 2002;98(2):63-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12048741/pubmed" id="12048741" target="_blank">12048741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35582951">
<a name="35582951"></a>Ahmed A, Affleck AG, Angus J, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of adults with delusional infestation 2022. <i>Br J Dermatol.</i> 2022;187(4):472-480. doi:10.1111/bjd.21668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/35582951/pubmed" id="35582951" target="_blank">35582951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15728443">
<a name="15728443"></a>Aichhorn W, Stuppaeck C, Whitworth AB. Risperidone and breast-feeding. <i>J Psychopharmacol</i>. 2005;19(2):211-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15728443/pubmed" id="15728443" target="_blank">15728443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16702902">
<a name="16702902"></a>Al Chekakie MO, Ketz JM, Whinney CM. Hypothermia in a patient receiving risperidone and paroxetine. <i>J Clin Psychopharmacol</i>. 2006;26(3):332-333. doi:10.1097/01.jcp.0000220525.52528.d7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16702902/pubmed" id="16702902" target="_blank">16702902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27093218">
<a name="27093218"></a>Al-Dhaher Z, Kapoor S, Saito E, et al. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in Youth. <i>J Child Adolesc Psychopharmacol</i>. 2016;26(5):458-470. doi:10.1089/cap.2015.0141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27093218/pubmed" id="27093218" target="_blank">27093218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31524318">
<a name="31524318"></a>Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. <i>Obes Rev</i>. 2019;20(12):1680-1690. doi:10.1111/obr.12934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31524318/pubmed" id="31524318" target="_blank">31524318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12153826">
<a name="12153826"></a>Aman MG, De Smedt G, Derivan A, et al, "Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage Intelligence," <i>Am J Psychiatry</i>, 2002, 159(8):1337-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12153826/pubmed" id="12153826" target="_blank">12153826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), “Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Diabetes Care</i>. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14981231">
<a name="14981231"></a>American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. <i>Obes Res.</i> 2004;12(2):362-368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14981231/pubmed" id="14981231" target="_blank">14981231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20075651">
<a name="20075651"></a>Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. <i>J Clin Psychopharmacol</i>. 2010;30(1):68-71. doi:10.1097/JCP.0b013e3181c8273d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20075651/pubmed" id="20075651" target="_blank">20075651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther.</i> 2016;100(1):42-52. doi: 10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30375086">
<a name="30375086"></a>Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. <i>Psychiatry Clin Neurosci</i>. 2019;73(1):27-33. doi:10.1111/pcn.12793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30375086/pubmed" id="30375086" target="_blank">30375086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29397667">
<a name="29397667"></a>Ardic UA, Küçükköse M, Inci SB, Ercan ES. Efficacy and safety profile of risperidone long-acting injection in adolescents in a real-life setting. <i>Clin Psychopharmacol Neurosci</i>. 2018;16(1):57-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29397667/pubmed" id="29397667" target="_blank">29397667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36051502">
<a name="36051502"></a>Ateb S, Fourati T, Ben Rejeb H, Januel D, Bouaziz N. Risperidone-induced priapism: a case report and literature review. <i>Ther Adv Psychopharmacol</i>. 2022;12:20451253221113246. doi: 10.1177/20451253221113246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/36051502/pubmed" id="36051502" target="_blank">36051502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289703">
<a name="15289703"></a>Bahk WM, Yoon JS, Kim YH, et al. Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. <i>Int Clin Psychopharmacol.</i> 2004;19(5):299-303. doi: 10.1097/01.yic.0000138821.85744.20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15289703/pubmed" id="15289703" target="_blank">15289703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31856527">
<a name="31856527"></a>Balamurugan R, Gupta PC, Kashyap H, Ram J. Risperidone-induced cataract in a young female. <i>Indian J Ophthalmol</i>. 2020;68(1):214. doi:10.4103/ijo.IJO_1517_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31856527/pubmed" id="31856527" target="_blank">31856527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20075665">
<a name="20075665"></a>Batalla A, Vera M, Torra M, Parellada E. Antipsychotic treatment in a patient with schizophrenia undergoing hemodialysis. <i>J Clin Psychopharmacol</i>. 2010;30(1):92-94. doi:10.1097/JCP.0b013e3181c827c4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20075665/pubmed" id="20075665" target="_blank">20075665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26542690">
<a name="26542690"></a>Baytunca MB, Kose S, Ozbaran B, Erermis S. Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent. <i>Pediatr Int</i>. 2016;58(1):61-63. doi:10.1111/ped.12741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26542690/pubmed" id="26542690" target="_blank">26542690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23295003">
<a name="23295003"></a>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. <i>Psychosomatics</i>. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23295003/pubmed" id="23295003" target="_blank">23295003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29275963">
<a name="29275963"></a>Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, torsades de pointes, and psychotropic medications: a 5-year Update. <i>Psychosomatics</i>. 2018;59(2):105-122. doi:10.1016/j.psym.2017.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29275963/pubmed" id="29275963" target="_blank">29275963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12934975">
<a name="12934975"></a>Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. <i>J Clin Psychiatry</i>. 2003;64(7):761-766. doi:10.4088/jcp.v64n0704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12934975/pubmed" id="12934975" target="_blank">12934975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29713106">
<a name="29713106"></a>Bhattacharjee D, Yerrapragada D, Chogtu B, Thomson SR. Risperidone induced isolated thrombocytopenia: a rare adverse event. <i>Psychopharmacol Bull</i>. 2018;48(3):47-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29713106/pubmed" id="29713106" target="_blank">29713106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958039">
<a name="19958039"></a>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. <i>CNS Drugs</i>. 2009;23(12):1003-1021. doi:10.2165/11530020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19958039/pubmed" id="19958039" target="_blank">19958039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32856174">
<a name="32856174"></a>Billnitzer A, Jankovic J. Current management of tics and Tourette syndrome: behavioral, pharmacologic, and surgical treatments. <i>Neurotherapeutics</i>. 2020;17(4):1681-1693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/32856174/pubmed" id="32856174" target="_blank">32856174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983962">
<a name="23983962"></a>Bishop JR, Rubin LH, Reilly JL, Pavuluri MN, Sweeney JA. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. <i>Ther Adv Psychopharmacol</i>. 2012;2(3):95-102. doi:10.1177/2045125312442080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23983962/pubmed" id="23983962" target="_blank">23983962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18030657">
<a name="18030657"></a>Blaschke D, Parwani AS, Huemer M, et al. Torsade de pointes during combined treatment with risperidone and citalopram. <i>Pharmacopsychiatry</i>. 2007;40(6):294-295. doi:10.1055/s-2007-992147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18030657/pubmed" id="18030657" target="_blank">18030657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24171144">
<a name="24171144"></a>Boarati MA, Wang YP, Ferreira-Maia AP, Cavalcanti AR, Fu-I L. Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder. <i>Prim Care Companion CNS Disord</i>. 2013;15(3):PCC.12m01368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24171144/pubmed" id="24171144" target="_blank">24171144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12623765">
<a name="12623765"></a>Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. <i>J Sex Marital Ther</i>. 2003;29(2):125-147. doi:10.1080/713847170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12623765/pubmed" id="12623765" target="_blank">12623765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19113797">
<a name="19113797"></a>Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. <i>Pharmacotherapy</i>. 2009;29(1):64-73. doi:10.1592/phco.29.1.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19113797/pubmed" id="19113797" target="_blank">19113797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12633121">
<a name="12633121"></a>Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. <i>J Clin Psychiatry</i>. 2003;64(2):134-143. doi: 10.4088/jcp.v64n0205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12633121/pubmed" id="12633121" target="_blank">12633121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11235929">
<a name="11235929"></a>Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. <i>J Clin Psychiatry</i>. 2001;62(1):50-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11235929/pubmed" id="11235929" target="_blank">11235929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19364288">
<a name="19364288"></a>Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2009;19(2):101-109. doi:10.1089/cap.2008.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19364288/pubmed" id="19364288" target="_blank">19364288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20331935">
<a name="20331935"></a>Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. <i>J Clin Psychiatry</i>. 2010;71(3):338-347. doi:10.4088/JCP.08m04595gre<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20331935/pubmed" id="20331935" target="_blank">20331935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):S7-S57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16916137">
<a name="16916137"></a>Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. <i>J Natl Med Assoc.</i> 2006;98(8):1353-1355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16916137/pubmed" id="16916137" target="_blank">16916137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12927004">
<a name="12927004"></a>Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. <i>J Clin Psychiatry</i>. 2003;64(8):898-906. doi:10.4088/jcp.v64n0807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12927004/pubmed" id="12927004" target="_blank">12927004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;65 Suppl 7:4-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28726075">
<a name="28726075"></a>Ceylan MF, Erdogan B, Tural Hesapcioglu S, Cop E. Effectiveness, adverse effects and drug compliance of long-acting injectable risperidone in children and adolescents. <i>Clin Drug Investig</i>. 2017;37(10):947-956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28726075/pubmed" id="28726075" target="_blank">28726075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30618887">
<a name="30618887"></a>Chen TR, Chen YC. Risperidone-associated neuroleptic malignant syndrome in an inpatient with schizophrenia, with successful rechallenge and 3 year follow-up. <i>Front Psychiatry</i>. 2018;9:718. doi:10.3389/fpsyt.2018.00718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30618887/pubmed" id="30618887" target="_blank">30618887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36974234">
<a name="36974234"></a>Cichon GJ, Qadri SF. Risperidone-induced sexual dysfunction case report. <i>Cureus</i>. 2023;15(2):e35357. doi:10.7759/cureus.35357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/36974234/pubmed" id="36974234" target="_blank">36974234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28141623">
<a name="28141623"></a>Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. <i>J Clin Psychopharmacol</i>. 2017;37(2):138-147. doi:10.1097/JCP.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28141623/pubmed" id="28141623" target="_blank">28141623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10718830">
<a name="10718830"></a>Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clin Endocrinol (Oxf)</i>. 2000;52(3):319-327. doi:10.1046/j.1365-2265.2000.00902.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10718830/pubmed" id="10718830" target="_blank">10718830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7488898">
<a name="7488898"></a>Cooney C, Nagy A. Angio-oedema associated with risperidone. <i>BMJ</i>. 1995;311(7014):1204. doi:10.1136/bmj.311.7014.1204c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/7488898/pubmed" id="7488898" target="_blank">7488898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533766">
<a name="18533766"></a>Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>J Clin Psychiatry</i>. 2008;69 Suppl 4:26-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18533766/pubmed" id="18533766" target="_blank">18533766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19861668">
<a name="19861668"></a>Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appears in <i>JAMA</i>. 2009;302(21):2322]. <i>JAMA</i>. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19861668/pubmed" id="19861668" target="_blank">19861668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15096079">
<a name="15096079"></a>Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.<i> J Clin Psychiatry.</i> 2004;65(3):386-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15096079/pubmed" id="15096079" target="_blank">15096079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9934953">
<a name="9934953"></a>Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. <i>J Clin Psychopharmacol.</i> 1999;19(1):101-103. doi: 10.1097/00004714-199902000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9934953/pubmed" id="9934953" target="_blank">9934953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26574175">
<a name="26574175"></a>Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. <i>Br J Clin Pharmacol</i>. 2016;81(4):773-783. doi:10.1111/bcp.12829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26574175/pubmed" id="26574175" target="_blank">26574175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9373440">
<a name="9373440"></a>Dernovsek Z, Tavcar R. Risperidone-induced leucopenia and neutropenia. <i>Br J Psychiatry</i>. 1997;171:393-394. doi:10.1192/bjp.171.4.393d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9373440/pubmed" id="9373440" target="_blank">9373440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11799340">
<a name="11799340"></a>Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. <i>J Clin Psychopharmacol.</i> 2002;22(1):31-39. doi: 10.1097/00004714-200202000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11799340/pubmed" id="11799340" target="_blank">11799340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24995318">
<a name="24995318"></a>Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. <i>Biomed Res Int</i>. 2014;2014:656370. doi:10.1155/2014/656370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24995318/pubmed" id="24995318" target="_blank">24995318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590213">
<a name="25590213"></a>Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2015;100(2):363-370. doi:10.1210/jc.2014-3421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25590213/pubmed" id="25590213" target="_blank">25590213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18297579">
<a name="18297579"></a>Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. <i>Ann Clin Psychiatry.</i> 2008;20(1):1-3. doi: 10.1080/10401230701844802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18297579/pubmed" id="18297579" target="_blank">18297579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19494785">
<a name="19494785"></a>Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i>Int Clin Psychopharmacol</i>. 2009;24(4):204-213. doi:10.1097/YIC.0b013e32832d6c18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19494785/pubmed" id="19494785" target="_blank">19494785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278567">
<a name="23278567"></a>Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. <i>J Forensic Sci</i>. 2013;58(2):398-403. doi:10.1111/1556-4029.12044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23278567/pubmed" id="23278567" target="_blank">23278567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11882064">
<a name="11882064"></a>Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. <i>Eur J Neurol</i>. 2002;9(2):182-183. doi: 10.1046/j.1468-1331.2002.0354e.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11882064/pubmed" id="11882064" target="_blank">11882064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15572275">
<a name="15572275"></a>Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>Eur Neuropsychopharmacol.</i> 2005;15(1):69-74. doi: 10.1016/j.euroneuro.2004.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15572275/pubmed" id="15572275" target="_blank">15572275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15610330">
<a name="15610330"></a>Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. <i>J Gen Intern Med</i>. 2004;19(12):1200-1205. doi:10.1111/j.1525-1497.2004.40126.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15610330/pubmed" id="15610330" target="_blank">15610330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24931938">
<a name="24931938"></a>Fear CF, Libretto SE. Risperidone for the treatment of delusional disorder. <i>Int J Psychiatry Clin Pract.</i> 2002;6(2):113-116. doi: 10.1080/136515002753724126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24931938/pubmed" id="24931938" target="_blank">24931938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15056514">
<a name="15056514"></a>Findling RL, Aman MG, Eerdekens M, et al, "Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQ," <i>Am J Psychiatry</i>, 2004, 161(4):677-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15056514/pubmed" id="15056514" target="_blank">15056514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9619165">
<a name="9619165"></a>Finkel B, Lerner AG, Oyffe I, Sigal M. Risperidone-associated agranulocytosis. <i>Am J Psychiatry</i>. 1998;155(6):855-856. doi:10.1176/ajp.155.6.855a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9619165/pubmed" id="9619165" target="_blank">9619165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23 Suppl 1:27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20853271">
<a name="20853271"></a>Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. <i>Eur J Ophthalmol</i>. 2011;21(2):210-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20853271/pubmed" id="20853271" target="_blank">20853271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29381388">
<a name="29381388"></a>Fortea A, Ilzarbe D, Espinosa L, et al. Long-acting injectable atypical antipsychotic use in adolescents: an observational study. <i>J Child Adolesc Psychopharmacol</i>. 2018;28(4):252-257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29381388/pubmed" id="29381388" target="_blank">29381388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25581312">
<a name="25581312"></a>Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. <i>JAMA Intern Med</i>. 2015;175(3):450-452. doi:10.1001/jamainternmed.2014.6930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25581312/pubmed" id="25581312" target="_blank">25581312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794644">
<a name="18794644"></a>Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol</i>. 2008;28(5):500-508. doi: 10.1097/JCP.0b013e318185e774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18794644/pubmed" id="18794644" target="_blank">18794644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gambhir.2014">
<a name="Gambhir.2014"></a>Gambhir S, Sandersfeld N, D'Mello D. A case of severe, refractory antipsychotic-induced orthostatic hypotension. <i>Medical Student Research Journal</i>. 2014;4:15-17.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24003306">
<a name="24003306"></a>Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. <i>Neuropsychiatr Dis Treat</i>. 2013;9:1145-1157. doi:10.2147/NDT.S41333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24003306/pubmed" id="24003306" target="_blank">24003306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24158020">
<a name="24158020"></a>Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. <i>J Clin Psychopharmacol</i>. 2014;34(1):109-123. doi:10.1097/JCP.0b013e3182a6096e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24158020/pubmed" id="24158020" target="_blank">24158020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26912127">
<a name="26912127"></a>Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. <i>World J Biol Psychiatry.</i> 2016;17(2):86-128. doi: 10.3109/15622975.2015.1132007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26912127/pubmed" id="26912127" target="_blank">26912127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25379316">
<a name="25379316"></a>Ginory A, Nguyen M. A case of priapism with risperidone. <i>Case Rep Psychiatry</i>. 2014;2014:241573. doi:10.1155/2014/241573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25379316/pubmed" id="25379316" target="_blank">25379316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. Renal pharmacotherapy: dosage adjustment of medications eliminated by the kidneys. Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24860681">
<a name="24860681"></a>Gómez Ramos MJ, Miguel González Valverde F, Sánchez Álvarez C, Ortin Katnich L, Pastor Quirante F. Fatal heat stroke in a schizophrenic patient. <i>Case Rep Crit Care</i>. 2012;2012:924328. doi:10.1155/2012/924328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24860681/pubmed" id="24860681" target="_blank">24860681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26658084">
<a name="26658084"></a>Gonzalez LS, Kothari K, Kasle DA. Three cases of late onset angioedema in nursing home human immunodeficiency virus patients on ritonavir and risperidone. <i>J Clin Psychopharmacol</i>. 2016;36(1):95-97. doi:10.1097/JCP.0000000000000449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26658084/pubmed" id="26658084" target="_blank">26658084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21206607">
<a name="21206607"></a>Gowda BS, Heebbar S, Sathyanarayana MT. Delusional parasitosis responding to risperidone.<i> Indian J Psychiatry.</i> 2002;44(4):382-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21206607/pubmed" id="21206607" target="_blank">21206607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27685194">
<a name="27685194"></a>Grau K, Plener PL, Gahr M, Denzer C, Freudenmann RW. Mild hypothermia in a child with low-dose risperidone. <i>Z Kinder Jugendpsychiatr Psychother</i>. 2017;45(4):335-337. doi:10.1024/1422-4917/a000484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27685194/pubmed" id="27685194" target="_blank">27685194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774943">
<a name="31774943"></a>Gründer P, Augustin M, Paulzen M, Gründer G. Influence of kidney function on serum risperidone concentrations in patients treated with risperidone. <i>J Clin Psychiatry</i>. 2019;80(6):19m12890. doi:10.4088/JCP.19m12890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31774943/pubmed" id="31774943" target="_blank">31774943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published correction appears in <i>World J Biol Psychiatry</i>. 2009;10(3):255]. <i>World J Biol Psychiatry.</i> 2009;10(2):85-116. doi: 10.1080/15622970902823202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23336748">
<a name="23336748"></a>Güneş F, Batgi H, Akbal A, Canatan T. Angioedema - an unusual serious side effect of risperidone injection. <i>Clin Toxicol (Phila)</i>. 2013;51(2):122-123. doi:10.3109/15563650.2013.765010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23336748/pubmed" id="23336748" target="_blank">23336748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18655726">
<a name="18655726"></a>Gupta M, Annadatha S. Treating bipolar disorder in patients with renal failure having haemodialysis: two case reports. <i>Clin Pract Epidemiol Ment Health</i>. 2008;4:21. doi:10.1186/1745-0179-4-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18655726/pubmed" id="18655726" target="_blank">18655726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15456328">
<a name="15456328"></a>Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. <i>Drugs</i>. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15456328/pubmed" id="15456328" target="_blank">15456328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709949">
<a name="14709949"></a>Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. <i>J Clin Psychopharmacol</i>. 2004;24(1):62-69. doi:10.1097/01.jcp.0000104913.75206.62<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14709949/pubmed" id="14709949" target="_blank">14709949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25168784">
<a name="25168784"></a>Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. <i>CNS Drugs</i>. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25168784/pubmed" id="25168784" target="_blank">25168784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11806485">
<a name="11806485"></a>Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. <i>J Clin Psychiatry</i>. 2001;62 Suppl 27:15-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11806485/pubmed" id="11806485" target="_blank">11806485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20041474">
<a name="20041474"></a>Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. <i>Hum Psychopharmacol.</i> 2010;25(1):37-46. doi: 10.1002/hup.1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20041474/pubmed" id="20041474" target="_blank">20041474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7520903">
<a name="7520903"></a>Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. <i>J Clin Psychiatry</i>. 1994;55(suppl):13-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/7520903/pubmed" id="7520903" target="_blank">7520903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW,et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10770482">
<a name="10770482"></a>Hill RC, McIvor RJ, Wojnar-Horton RE, Hackett LP, Ilett KF. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. <i>J Clin Psychopharmacol</i>. 2000;20(2):285-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10770482/pubmed" id="10770482" target="_blank">10770482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16633146">
<a name="16633146"></a>Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. <i>J Clin Psychopharmacol</i>. 2006;26(2):167-171. doi:10.1097/01.jcp.0000203194.58087.9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16633146/pubmed" id="16633146" target="_blank">16633146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11579015">
<a name="11579015"></a>Hong X, Wang X. Agranulocytosis and neutropenia with typical and atypical neuroleptics. <i>Am J Psychiatry</i>. 2001;158(10):1736-1737. doi:10.1176/appi.ajp.158.10.1736-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11579015/pubmed" id="11579015" target="_blank">11579015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000 Feb;157(2):172-8. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20473056">
<a name="20473056"></a>Hsu WY, Huang SS, Lee BS, Chiu NY. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. <i>J Clin Psychopharmacol.</i> 2010;30(3):230-234. doi: 10.1097/JCP.0b013e3181db8715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20473056/pubmed" id="20473056" target="_blank">20473056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29770221">
<a name="29770221"></a>Hui Fang CE, Rafey MF, Cunningham A, Dinneen SF, Finucane FM. Risperidone-induced type 2 diabetes presenting with diabetic ketoacidosis. <i>Endocrinol Diabetes Metab Case Rep</i>. 2018;2018:18-0031. doi:10.1530/EDM-18-0031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29770221/pubmed" id="29770221" target="_blank">29770221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288069">
<a name="21288069"></a>Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World</i>
<i>J Biol Psychiatry.</i> 2011;12(1):2-32. doi: 10.3109/15622975.2010.538083.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21288069/pubmed" id="21288069" target="_blank">21288069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14742766">
<a name="14742766"></a>Ilett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ. Transfer of risperidone and 9-hydroxyrisperidone into human milk. <i>Ann Pharmacother.</i> 2004;38(2):273-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14742766/pubmed" id="14742766" target="_blank">14742766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jibson.1">
<a name="Jibson.1"></a>Jibson MD. Second-generation antipsychotic medications: pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 6, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046641">
<a name="12046641"></a>Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. <i>Ann Clin Psychiatry</i>. 2002;14(1):59-64. doi:10.1023/a:1015228112495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12046641/pubmed" id="12046641" target="_blank">12046641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24416588">
<a name="24416588"></a>Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the general practice research database. <i>Cardiovasc Psychiatry Neurol</i>. 2013;2013:647476. doi:10.1155/2013/647476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24416588/pubmed" id="24416588" target="_blank">24416588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193526">
<a name="22193526"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22193526/pubmed" id="22193526" target="_blank">22193526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17478595">
<a name="17478595"></a>Karnik NS, Joshi SV, Paterno C, et al, "Subtypes of Pediatric Delirium: A Treatment Algorithm," <i>Psychosomatics</i>, 2007, 48(3):253-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17478595/pubmed" id="17478595" target="_blank">17478595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28794632">
<a name="28794632"></a>Kattalai Kailasam V, Chima V, Nnamdi U, Sharma K, Shah K. Risperidone-induced reversible neutropenia. <i>Neuropsychiatr Dis Treat</i>. 2017;13:1975-1977. doi:10.2147/NDT.S141472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28794632/pubmed" id="28794632" target="_blank">28794632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10084637">
<a name="10084637"></a>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M; Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. <i>J Clin Psychiatry</i>. 1999;60(2):107-115. doi: 10.4088/jcp.v60n0207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10084637/pubmed" id="10084637" target="_blank">10084637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des Troubles Anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.<i> BMC Psychiatry.</i> 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24851124">
<a name="24851124"></a>Kawabe K, Ueno S. A case of acute pancreatitis associated with risperidone treatment. <i>Clin Psychopharmacol Neurosci</i>. 2014;12(1):67-8. doi:10.9758/cpn.2014.12.1.67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24851124/pubmed" id="24851124" target="_blank">24851124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18586273">
<a name="18586273"></a>Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. <i>J Psychiatr Res</i>. 2009;43(3):205-214. doi: 10.1016/j.jpsychires.2008.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18586273/pubmed" id="18586273" target="_blank">18586273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20465623">
<a name="20465623"></a>Kenchaiah BK, Kumar S, Tharyan P. Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients. <i>Int J Dermatol</i>. 2010;49(1):95-100. doi: 10.1111/j.1365-4632.2009.04312.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20465623/pubmed" id="20465623" target="_blank">20465623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486148">
<a name="27486148"></a>Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. <i>Can J Psychiatry</i>. 2016;61(9):540-560. doi:10.1177/0706743716659417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27486148/pubmed" id="27486148" target="_blank">27486148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30702354">
<a name="30702354"></a>Khan S, Down J, Aouira N, et al. Current pharmacotherapy options for conduct disorders in adolescents and children. <i>Expert Opin Pharmacother</i>. 2019;20(5):571-583.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30702354/pubmed" id="30702354" target="_blank">30702354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093019">
<a name="31093019"></a>Kishk OA, Simone S, Lardieri AB, Graciano AL, Tumulty J, Edwards S. Antipsychotic treatment of delirium in critically ill children: a retrospective matched cohort study. <i>J Pediatr Pharmacol Ther</i>. 2019;24(3):204-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31093019/pubmed" id="31093019" target="_blank">31093019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21154393">
<a name="21154393"></a>Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. <i>Cochrane Database Syst Rev</i>. 2010;(12):CD008121. doi: 10.1002/14651858.CD008121.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21154393/pubmed" id="21154393" target="_blank">21154393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33674295">
<a name="33674295"></a>Konnakkaparambil Ramakrishnan K, George M. Deep vein thrombosis on the fourth day of risperidone therapy. <i>BMJ Case Rep</i>. 2021;14(3):e239569. doi: 10.1136/bcr-2020-239569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/33674295/pubmed" id="33674295" target="_blank">33674295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849776">
<a name="17849776"></a>Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>Am J Psychiatry.</i> 2007;164(7)(suppl):S5-S53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17849776/pubmed" id="17849776" target="_blank">17849776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Koran.2013">
<a name="Koran.2013"></a>Koran LM, Simpson HB; American Psychiatric Association. Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd-watch.pdf. Updated March 2013. Accessed November 6, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15869022">
<a name="15869022"></a>Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. <i>Essent Psychopharmacol</i>. 2005;6(3):148-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15869022/pubmed" id="15869022" target="_blank">15869022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28411574">
<a name="28411574"></a>Kulkarni K, Arasappa R, Prasad M K, et al. Risperidone versus olanzapine in the acute treatment of persistent delusional disorder: a retrospective analysis. <i>Psychiatry Res.</i> 2017;253:270-273. doi: 10.1016/j.psychres.2017.02.066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28411574/pubmed" id="28411574" target="_blank">28411574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14659983">
<a name="14659983"></a>Kutcher S, Aman M, Brooks SJ, et al, "International Consensus Statement on Attention-Deficit/Hyperactivity Disorder (ADHD) and Disruptive Behaviour Disorders (DBDs): Clinical Implications and Treatment Practice Suggestions," <i>Eur Neuropsychopharmacol</i>, 2004, 14(1):11-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14659983/pubmed" id="14659983" target="_blank">14659983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi: 10.1345/aph.1G130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737244">
<a name="23737244"></a>La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. <i>Pharmacopsychiatry</i>. 2013;46(6):201-208. doi:10.1055/s-0033-1347177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23737244/pubmed" id="23737244" target="_blank">23737244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi: 10.1111/acps.12479.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lauriello.1">
<a name="Lauriello.1"></a>Lauriello J, Campbell AR. Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26166241">
<a name="26166241"></a>Lee YF, Tsai CK, Liang CS. High-dose risperidone induced latent syndrome of inappropriate antidiuretic hormone secretion with seizure presentation. <i>Clin Neuropharmacol</i>. 2015;38(4):154-155. doi: 10.1097/WNF.0000000000000095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26166241/pubmed" id="26166241" target="_blank">26166241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810019">
<a name="23810019"></a>Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis [published correction appears in <i>Lancet</i>. 2013;382(9896):940]. <i>Lancet</i>. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23810019/pubmed" id="23810019" target="_blank">23810019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. <i>Schizophr</i>
<i>Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15960567">
<a name="15960567"></a>Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. <i>J Clin Psychiatry.</i> 2005;66(6):736-743. doi: 10.4088/jcp.v66n0610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15960567/pubmed" id="15960567" target="_blank">15960567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20523078">
<a name="20523078"></a>Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. <i>Neuropsychobiology</i>. 2010;62(2):81-86. doi: 10.1159/000315437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20523078/pubmed" id="20523078" target="_blank">20523078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33156585">
<a name="33156585"></a>Liu LY, Hsu CC. Risperidone-associated edema. <i>Am J Ther.</i> 2020;27(6):e667-e669. doi: 10.1097/MJT.0000000000001031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/33156585/pubmed" id="33156585" target="_blank">33156585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975181">
<a name="17975181"></a>Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. <i>Ann Intern Med</i>. 2007;147(9):593-602. doi: 10.7326/0003-4819-147-9-200711060-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17975181/pubmed" id="17975181" target="_blank">17975181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17366350">
<a name="17366350"></a>Makesar D, Thome J. Risperidone-induced priapism. <i>World J Biol Psychiatry</i>. 2007;8(1):45-47. doi:10.1080/15622970600797575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17366350/pubmed" id="17366350" target="_blank">17366350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794658">
<a name="18794658"></a>Mall GD, Hake L, Benjamin AB, Adityanjee A. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report. <i>J Clin Psychopharmacol</i>. 2008;28(5):572-573. doi:10.1097/JCP.0b013e318185a6ee<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18794658/pubmed" id="18794658" target="_blank">18794658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21127693">
<a name="21127693"></a>Maloney AE, Sikich L. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. <i>Neuropsychiatr Dis Treat</i>. 2010;6:749-766. doi:10.2147/NDT.S6614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21127693/pubmed" id="21127693" target="_blank">21127693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7507814">
<a name="7507814"></a>Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. <i>Drug Metab Dispos</i>. 1993;21(6):1134-1141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/7507814/pubmed" id="7507814" target="_blank">7507814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26226481">
<a name="26226481"></a>Masi G, Milone A, Stawinoga A, Veltri S, Pisano S. Efficacy and safety of risperidone and quetiapine in adolescents with bipolar II disorder comorbid with conduct disorder. <i>J Clin Psychopharmacol</i>. 2015;35(5):587-590. doi:10.1097/JCP.0000000000000371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26226481/pubmed" id="26226481" target="_blank">26226481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21150847">
<a name="21150847"></a>Mazhar MN, Resch DS. Risperidone induced ventricular tachycardia. <i>Psychopharmacol Bull</i>. 2010;43(3):82-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21150847/pubmed" id="21150847" target="_blank">21150847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30106879">
<a name="30106879"></a>Mazher OA, Maneta E, Hall W. Treatment of risperidone-associated hyperprolactinemia with aripiprazole. <i>J Clin Psychopharmacol</i>. 2018;38(5):529-531. doi:10.1097/JCP.0000000000000942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30106879/pubmed" id="30106879" target="_blank">30106879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10920469">
<a name="10920469"></a>McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.<i> Arch Gen Psychiatry.</i> 2000;57(8):794-801. doi: 10.1001/archpsyc.57.8.794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10920469/pubmed" id="10920469" target="_blank">10920469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17645196">
<a name="17645196"></a>Mercan S, Altunay IK, Taskintuna N, Ogutcen O, Kayaoğlu S. Atypical antipsychotic drugs in the treatment of delusional parasitosis. <i>Int J Psychiatry Med</i>. 2007;37(1):29-37. doi: 10.2190/M8M5-H1G2-1257-2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17645196/pubmed" id="17645196" target="_blank">17645196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15246458">
<a name="15246458"></a>Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. <i>Schizophr Res</i>. 2004;70(1):1-17. doi:10.1016/j.schres.2004.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15246458/pubmed" id="15246458" target="_blank">15246458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16001094">
<a name="16001094"></a>Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. <i>Prim Care Companion J Clin Psychiatry</i>. 2004;6(Suppl 2):3-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16001094/pubmed" id="16001094" target="_blank">16001094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30206502">
<a name="30206502"></a>Modesitt T, Kubascik E, Ott C. Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid. <i>Ment Health Clin</i>. 2018;8(5):202-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30206502/pubmed" id="30206502" target="_blank">30206502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. 2020;10:2045125320937910. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.1">
<a name="Moore.1"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25363101">
<a name="25363101"></a>Moosavi SM, Ahmadi M, Monajemi MB. Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial. <i>Glob J Health Sci.</i> 2014;6(6):163-167. doi: 10.5539/gjhs.v6n6p163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25363101/pubmed" id="25363101" target="_blank">25363101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morrato.2012">
<a name="Morrato.2012"></a>Morrato EH. An update on lipid profile screening in second-generation antipsychotic users in the USA. <i>Clinical Lipidology</i>. 2012;7(5):509-523. doi:10.2217/clp.12.51</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28558630">
<a name="28558630"></a>Morrison M, Schultz A, Sanchez DL, Catalano MC, Catalano G. Leukopenia associated with risperidone treatment [published online ahead of print May 30, 2017]. <i>Curr Drug Saf</i>. 2017;10.2174/1574886312666170531072837. doi:10.2174/1574886312666170531072837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28558630/pubmed" id="28558630" target="_blank">28558630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17239039">
<a name="17239039"></a>Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. <i>Psychiatry Clin Neurosci</i>. 2007;61(1):54-58. doi:10.1111/j.1440-1819.2007.01610.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17239039/pubmed" id="17239039" target="_blank">17239039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27283263">
<a name="27283263"></a>Nagamine T. Severe hypoglycemia associated with risperidone. <i>Psychiatry Clin Neurosci</i>. 2016;70(9):421. doi:10.1111/pcn.12416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27283263/pubmed" id="27283263" target="_blank">27283263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20048451">
<a name="20048451"></a>Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. <i>Indian J Psychiatry</i>. 2009;51(4):265-271. doi:10.4103/0019-5545.58291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20048451/pubmed" id="20048451" target="_blank">20048451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16431007">
<a name="16431007"></a>Narumoto J, Ueda H, Tsuchida H, Yamashita T, Kitabayashi Y, Fukui K. Regional cerebral blood flow changes in a patient with delusional parasitosis before and after successful treatment with risperidone: a case report. <i>Prog Neuropsychopharmacol Biol Psychiatry.</i> 2006;30(4):737-740. doi: 10.1016/j.pnpbp.2005.11.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16431007/pubmed" id="16431007" target="_blank">16431007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065063">
<a name="26065063"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. https://www.nice.org.uk/guidance/cg155
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26065063/pubmed" id="26065063" target="_blank">26065063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated). National Clinical Practice Guideline Number 82, 2009:1-399. www.nice.org.uk/cg082.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19687129">
<a name="19687129"></a>Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. <i>Am J Psychiatry</i>. 2009;166(9):980-991. doi: 10.1176/appi.ajp.2009.09030312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19687129/pubmed" id="19687129" target="_blank">19687129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;19 Suppl 1:1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17671284">
<a name="17671284"></a>Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. <i>Am J Psychiatry. </i>2007;164(8):1214-1220. doi: 10.1176/appi.ajp.2007.06111886.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17671284/pubmed" id="17671284" target="_blank">17671284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20520598">
<a name="20520598"></a>Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i>. 2010;35(9):1997-2004. doi:10.1038/npp.2010.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20520598/pubmed" id="20520598" target="_blank">20520598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17124642">
<a name="17124642"></a>Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. <i>Pharmacopsychiatry</i>. 2006;39(6):209-212. doi:10.1055/s-2006-950498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17124642/pubmed" id="17124642" target="_blank">17124642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22533871">
<a name="22533871"></a>Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. <i>J Sex Marital Ther</i>. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22533871/pubmed" id="22533871" target="_blank">22533871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012695">
<a name="17012695"></a>Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. <i>Am J Psychiatry</i>. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17012695/pubmed" id="17012695" target="_blank">17012695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34224426">
<a name="34224426"></a>Ou H, Chang HA, Kao YC, Tzeng NS. Risperidone-induced acute urinary retention in a patient with major depressive disorder with psychotic features: a case report. <i>Am J Ther</i>. 2021;21;28(5):e585-e587. doi:10.1097/MJT.0000000000001414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/34224426/pubmed" id="34224426" target="_blank">34224426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568278">
<a name="27568278"></a>Pacchiarotti I, León-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578. doi: 10.1016/j.euroneuro.2016.08.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27568278/pubmed" id="27568278" target="_blank">27568278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983987">
<a name="23983987"></a>Paklet L, Abe AM, Olajide D. Priapism associated with risperidone: a case report, literature review and review of the South London and Maudsley hospital patients' database. <i>Ther Adv Psychopharmacol</i>. 2013;3(1):3-13. doi:10.1177/2045125312464104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23983987/pubmed" id="23983987" target="_blank">23983987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16958564">
<a name="16958564"></a>Pandina GJ, Aman MG, and Findling RL, "Risperidone in the Management of Disruptive Behavior Disorders," <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(4):379-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16958564/pubmed" id="16958564" target="_blank">16958564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16906015">
<a name="16906015"></a>Parraga H, Harris K. Catatonia under treatment with risperidone. <i>J Dev Behav Pediatr</i>. 2006;27(4):369. doi:10.1097/00004703-200608000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16906015/pubmed" id="16906015" target="_blank">16906015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10950488">
<a name="10950488"></a>Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. <i>J Clin Psychopharmacol.</i> 1997;17(2):134-135. doi: 10.1097/00004714-199704000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10950488/pubmed" id="10950488" target="_blank">10950488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24171143">
<a name="24171143"></a>Patel A, Malek N, Haq F, Turnbow L, Raza S. Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report. <i>Prim Care Companion CNS Disord</i>. 2013;15(3):PCC.12l01454. doi:10.4088/PCC.12l01454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24171143/pubmed" id="24171143" target="_blank">24171143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24688758">
<a name="24688758"></a>Perera MA, Yogaratnam J. De Novo delayed onset hypothermia secondary to therapeutic doses of risperidone in bipolar affective disorder. <i>Ther Adv Psychopharmacol</i>. 2014;4(2):70-74. doi:10.1177/2045125313507740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24688758/pubmed" id="24688758" target="_blank">24688758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35245409">
<a name="35245409"></a>Perlstein I, Merenlender Wagner A, Gomeni R, et al. Population pharmacokinetic modeling and simulation of TV-46000: a long-acting injectable formulation of risperidone. <i>Clin Pharmacol Drug Dev</i>. 2022;11(7):865-877. doi:10.1002/cpdd.1078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/35245409/pubmed" id="35245409" target="_blank">35245409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perseris.1">
<a name="Perseris.1"></a>Perseris (risperidone) [prescribing information]. North Chesterfield, VA: Indivior Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perseris.2">
<a name="Perseris.2"></a>Perseris (risperidone) [product monograph]. Etobicoke, Ontario, Canada: HLS Therapeutics Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27592232">
<a name="27592232"></a>Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. <i>Psychopharmacology (Berl)</i>. 2016;233(21-22):3663-3672. doi:10.1007/s00213-016-4411-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27592232/pubmed" id="27592232" target="_blank">27592232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397999">
<a name="22397999"></a>Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143. doi: 10.1177/070674371205700302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22397999/pubmed" id="22397999" target="_blank">22397999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25886655">
<a name="25886655"></a>Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. <i>Can J Psychiatry</i>. 2015;60(2):42-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25886655/pubmed" id="25886655" target="_blank">25886655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906. doi: 10.1212/WNL.0000000000007466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19287562">
<a name="19287562"></a>Qureshi SU, Rubin E. Risperidone- and aripiprazole-induced leukopenia: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2008;10(6):482-483. doi:10.4088/pcc.v10n0612c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19287562/pubmed" id="19287562" target="_blank">19287562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16175125">
<a name="16175125"></a>Railton CJ, Kapur B, Koren G. Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle. <i>Ther Drug Monit</i>. 2005;27(5):558-561. doi:10.1097/01.ftd.0000168720.19867.43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16175125/pubmed" id="16175125" target="_blank">16175125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17604410">
<a name="17604410"></a>Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. <i>Drug Saf</i>. 2007;30(7):589-599. doi:10.2165/00002018-200730070-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17604410/pubmed" id="17604410" target="_blank">17604410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15133539">
<a name="15133539"></a>Razaq M, Samma M. A case of risperidone-induced hypothermia. <i>Am J Ther</i>. 2004;11(3):229-230. doi:10.1097/00045391-200405000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15133539/pubmed" id="15133539" target="_blank">15133539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. doi: 10.1176/appi.ajp.2015.173501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22302895">
<a name="22302895"></a>Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. <i>J Psychopharmacol.</i> 1996;10(2):162-165. doi: 10.1177/026988119601000213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22302895/pubmed" id="22302895" target="_blank">22302895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16513860">
<a name="16513860"></a>Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. <i>Am J Psychiatry</i>. 2006;163(3):402-410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16513860/pubmed" id="16513860" target="_blank">16513860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340682">
<a name="10340682"></a>Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60 suppl 10:5-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10340682/pubmed" id="10340682" target="_blank">10340682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Risperdal.1">
<a name="Risperdal.1"></a>Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Risperdal.2">
<a name="Risperdal.2"></a>Risperdal (risperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Risperdal.3">
<a name="Risperdal.3"></a>Risperdal Consta (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Risperdal.4">
<a name="Risperdal.4"></a>Risperdal Consta (risperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Risperidone.1">
<a name="Risperidone.1"></a>Risperidone Orally Disintegrating Tablets (risperidone) [prescribing information]. Princeton, NJ: Sandoz Inc; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338693">
<a name="26338693"></a>Robinson DG, Gallego JA, John M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. <i>Schizophr Bull.</i> 2015;41(6):1227-1236. doi: 10.1093/schbul/sbv125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26338693/pubmed" id="26338693" target="_blank">26338693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21445724">
<a name="21445724"></a>Roessner V, Plessen KJ, Rothenberger A, et al; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196. doi: 10.1007/s00787-011-0163-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21445724/pubmed" id="21445724" target="_blank">21445724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10950485">
<a name="10950485"></a>Safer DL, Wenegrat B, Roth WT. Risperidone in the treatment of delusional parasitosis: a case report. <i>J Clin Psychopharmacol.</i> 1997;17(2):131-132. doi: 10.1097/00004714-199704000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10950485/pubmed" id="10950485" target="_blank">10950485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686794">
<a name="29686794"></a>Samra GS, Kant S, Chow R. Risperidone induced angioedema with concurrent EPS symptoms: a case report and review of literature. <i>J Community Hosp Intern Med Perspect</i>. 2018;8(2):80-83. doi:10.1080/20009666.2018.1447215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29686794/pubmed" id="29686794" target="_blank">29686794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12682319">
<a name="12682319"></a>Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. <i>Neurology</i>. 2003;60(7):1130-1135. doi: 10.1212/01.wnl.0000055434.39968.67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12682319/pubmed" id="12682319" target="_blank">12682319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17457571">
<a name="17457571"></a>Schieveld JN, Leroy PL, van Os J, et al, "Pediatric Delirium in Critical Illness: Phenomenology, Clinical Correlates and Treatment Response in 40 Cases in the Pediatric Intensive Care Unit," <i>Intensive Care Med</i>, 2007, 33(6):1033-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17457571/pubmed" id="17457571" target="_blank">17457571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30838312">
<a name="30838312"></a>Schultz JL, Kamholz JA, Nopoulos PC, Killoran A. Comparing risperidone and olanzapine to tetrabenazine for the management of chorea in Huntington disease: an analysis from the enroll-HD database. <i>Mov Disord Clin Pract.</i> 2018;6(2):132-138. doi: 10.1002/mdc3.12706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30838312/pubmed" id="30838312" target="_blank">30838312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19134517">
<a name="19134517"></a>Semba J, Okui S. Risperidone-induced thrombocytopenia: a case report. <i>Gen Hosp Psychiatry</i>. 2009;31(1):97-98. doi:10.1016/j.genhosppsych.2008.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19134517/pubmed" id="19134517" target="_blank">19134517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21191308">
<a name="21191308"></a>Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>Int Clin Psychopharmacol</i>. 2011;26(3):130-140. doi:10.1097/YIC.0b013e328341e434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21191308/pubmed" id="21191308" target="_blank">21191308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439747">
<a name="32439747"></a>Sharma N, Bhat S, Ravi D, Ochieng P. Severe hypothermia, bradycardia and cardiac arrest in association with risperidone. <i>BMJ Case Rep</i>. 2020;13(5):e234999. doi:10.1136/bcr-2020-234999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/32439747/pubmed" id="32439747" target="_blank">32439747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27924205">
<a name="27924205"></a>Shin YH, Lee SH, Kim DY. Risperidone in a child with untractable emergency delirium: a case report. <i>Korean J Anesthesiol</i>. 2016;69(6):623-626.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27924205/pubmed" id="27924205" target="_blank">27924205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20889664">
<a name="20889664"></a>Silver GH, Kearney JA, Kutko MC, et al, "Infant Delirium in Pediatric Critical Care Settings," <i>Am J Psychiatry</i>, 2010, 167(10):1172-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20889664/pubmed" id="20889664" target="_blank">20889664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28410275">
<a name="28410275"></a>Simone S, Edwards S, Lardieri A, et al. Implementation of an ICU bundle: an interprofessional quality improvement project to enhance delirium management and monitor delirium prevalence in a single PICU. <i>Pediatr Crit Care Med</i>. 2017;18(6):531-540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28410275/pubmed" id="28410275" target="_blank">28410275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24026523">
<a name="24026523"></a>Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. <i>JAMA Psychiatry.</i> 2013;70(11):1190-1199. doi: 10.1001/jamapsychiatry.2013.1932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24026523/pubmed" id="24026523" target="_blank">24026523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20848326">
<a name="20848326"></a>Singer HS, "Treatment of Tics and Tourette Syndrome," <i>Curr Treat Options Neurol</i>, 2010, 12(6):539-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20848326/pubmed" id="20848326" target="_blank">20848326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23238761">
<a name="23238761"></a>Singh V, Bowden CL, Mintz J. Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. <i>Int Clin Psychopharmacol</i>. 2013;28(2):91-95. doi: 10.1097/YIC.0b013e32835c7590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23238761/pubmed" id="23238761" target="_blank">23238761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23639666">
<a name="23639666"></a>Smith HA, Brink E, Fuchs DC, Ely EW, Pandharipande PP. Pediatric delirium: monitoring and management in the pediatric intensive care unit. <i>Pediatr Clin North Am</i>. 2013;60(3):741-760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23639666/pubmed" id="23639666" target="_blank">23639666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8748391">
<a name="8748391"></a>Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. <i>Psychopharmacology (Berl)</i>. 1995;122(3):223-229. doi:10.1007/BF02246543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/8748391/pubmed" id="8748391" target="_blank">8748391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169. doi:10.1055/s-2007-971169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi: 10.2147/TCRM.S117321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8599414">
<a name="8599414"></a>Songer DA, Roman B. Treatment of somatic delusional disorder with atypical antipsychotic agents. <i>Am J Psychiatry</i>. 1996;153(4):578-579. doi: 10.1176/ajp.153.4.578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/8599414/pubmed" id="8599414" target="_blank">8599414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35342201">
<a name="35342201"></a>Sood S. A case report of stuttering induced by risperidone and chlorpromazine. <i>Psychopharmacol Bull</i>. 2022;52(1):53-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/35342201/pubmed" id="35342201" target="_blank">35342201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21112458">
<a name="21112458"></a>Soumya RN, Grover S, Dutt A, Gaur N. Angioneurotic edema with risperidone: a case report and review of literature. <i>Gen Hosp Psychiatry</i>. 2010;32(6):646.e1-646.e6463. doi:10.1016/j.genhosppsych.2010.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21112458/pubmed" id="21112458" target="_blank">21112458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343447">
<a name="23343447"></a>Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. <i>Curr Clin Pharmacol</i>. 2014;9(3):310-317. doi: 10.2174/15748847113089990051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23343447/pubmed" id="23343447" target="_blank">23343447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steinman.1">
<a name="Steinman.1"></a>Steinman M, Reeve E. Deprescribing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096514">
<a name="16096514"></a>Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. <i>Int Clin Psychopharmacol</i>. 2005;20(5):243-251. doi:10.1097/01.yic.0000166405.49473.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16096514/pubmed" id="16096514" target="_blank">16096514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30192094">
<a name="30192094"></a>Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i>. 2018;17(3):341-356. doi:10.1002/wps.20567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/30192094/pubmed" id="30192094" target="_blank">30192094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.2">
<a name="Stroup.2"></a>Stroup TS, Marder S. Schizophrenia in adults: Maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suchowersky.1">
<a name="Suchowersky.1"></a>Suchowersky O. Huntington disease: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suh.1">
<a name="Suh.1"></a>Suh KN. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29369497">
<a name="29369497"></a>Sukasem C, Vanwong N, Srisawasdi P, et al. Pharmacogenetics of risperidone-induced insulin resistance in children and adolescents with autism spectrum disorder. <i>Basic Clin Pharmacol Toxicol</i>. 2018;123(1):42-50. doi:10.1111/bcpt.12970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29369497/pubmed" id="29369497" target="_blank">29369497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18519523">
<a name="18519523"></a>Sultzer DL, Davis SM, Tariot PN, et al; CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. <i>Am J Psychiatry</i>. 2008;165(7):844-854. doi: 10.1176/appi.ajp.2008.07111779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18519523/pubmed" id="18519523" target="_blank">18519523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull.</i> 2017;43(4):862-871. doi: 10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taro-Risperidone.1">
<a name="Taro-Risperidone.1"></a>Taro-Risperidone (risperidone) tablets [product monograph]. Brampton, Ontario, Canada: Sun Pharma Canada Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15345794">
<a name="15345794"></a>Tei Y, Morita T, Inoue S, Miyata H. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. <i>Psychosomatics</i>. 2004;45(5):450-451. doi:10.1176/appi.psy.45.5.450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15345794/pubmed" id="15345794" target="_blank">15345794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9501892">
<a name="9501892"></a>Terao T, Kojima H, Eto A. Risperidone and allergic reactions. <i>J Clin Psychiatry</i>. 1998;59(2):82-83. doi:10.4088/jcp.v59n0207c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9501892/pubmed" id="9501892" target="_blank">9501892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28867897">
<a name="28867897"></a>Thomson SR, Chogtu B, Bhattacharjee D, Agarwal S. Extrapyramidal symptoms probably related to risperidone treatment: a case series. <i>Ann Neurosci</i>. 2017;24(3):155-163. doi:10.1159/000477153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28867897/pubmed" id="28867897" target="_blank">28867897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981]. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3 Pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31857937">
<a name="31857937"></a>Tourtellotte R, Schmidt R. Use of therapeutic drug monitoring of risperidone microspheres long-acting injection in hemodialysis: a case report. <i>Ment Health Clin</i>. 2019;9(6):404-407. doi:10.9740/mhc.2019.11.404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31857937/pubmed" id="31857937" target="_blank">31857937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898718">
<a name="24898718"></a>Turkel SB, Hanft A. The pharmacologic management of delirium in children and adolescents. <i>Paediatr Drugs</i>. 2014;16(4):267-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24898718/pubmed" id="24898718" target="_blank">24898718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22364403">
<a name="22364403"></a>Turkel SB, Jacobson J, Munzig E, Tavaré CJ. Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(2):126-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22364403/pubmed" id="22364403" target="_blank">22364403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23782129">
<a name="23782129"></a>Turkel SB, Jacobson JR, Tavaré CJ. The diagnosis and management of delirium in infancy. <i>J Child Adolesc Psychopharmacol</i>. 2013;23(5):352-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23782129/pubmed" id="23782129" target="_blank">23782129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15201572">
<a name="15201572"></a>Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. <i>Int Clin Psychopharmacol.</i> 2004;19(4):241-249. doi: 10.1097/01.yic.0000133500.92025.20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15201572/pubmed" id="15201572" target="_blank">15201572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27028982">
<a name="27028982"></a>Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27028982/pubmed" id="27028982" target="_blank">27028982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADod.1">
<a name="VADod.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Updated February 2022. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Uzedy.1">
<a name="Uzedy.1"></a>Uzedy (risperidone) [prescribing information]. Parsippany, NJ: Teva Neuroscience Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19264412">
<a name="19264412"></a>van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. <i>Psychoneuroendocrinology</i>. 2009;34(7):989-995. doi:10.1016/j.psyneuen.2009.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19264412/pubmed" id="19264412" target="_blank">19264412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31071486">
<a name="31071486"></a>Vellekkatt F, Kuppili PP, Bharadwaj B, Menon V. Atypical neuroleptic malignant syndrome - a case report. <i>Asian J Psychiatr</i>. 2019;43:7-8. doi:10.1016/j.ajp.2019.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31071486/pubmed" id="31071486" target="_blank">31071486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11869771">
<a name="11869771"></a>Vieta E, Gastó C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. <i>J Affect Disord.</i> 2001;67(1-3):213-219. doi: 10.1016/s0165-0327(01)00435-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11869771/pubmed" id="11869771" target="_blank">11869771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12204313">
<a name="12204313"></a>Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernández A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. <i>J Affect Disord.</i> 2002;72(1):15-19. doi: 10.1016/s0165-0327(01)00481-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12204313/pubmed" id="12204313" target="_blank">12204313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812796">
<a name="23812796"></a>Vieweg WV, Hasnain M, Hancox JC, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. <i>Psychopharmacology (Berl)</i>. 2013;228(4):515-524. doi:10.1007/s00213-013-3192-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23812796/pubmed" id="23812796" target="_blank">23812796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28636569">
<a name="28636569"></a>Vuk A, Kuzman MR, Baretic M, Osvatic MM. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. <i>Psychiatr Danub</i>. 2017;29(2):121-135. doi:10.24869/psyd.2017.121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28636569/pubmed" id="28636569" target="_blank">28636569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin</i>
<i>Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14971869">
<a name="14971869"></a>Wenning MT, Davy LE, Catalano G, Catalano MC. Atypical antipsychotics in the treatment of delusional parasitosis. <i>Ann Clin Psychiatry.</i> 2003;15(3-4):233-239. doi: 10.1023/b:acli.0000008687.21295.8a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14971869/pubmed" id="14971869" target="_blank">14971869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24919175">
<a name="24919175"></a>Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. <i>Braz J Med Biol Res</i>. 2014;47(7):605-616. doi:10.1590/1414-431x20143672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24919175/pubmed" id="24919175" target="_blank">24919175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31534873">
<a name="31534873"></a>Williams GD. Cross-reaction of angioedema with clozapine, olanzapine, and quetiapine: A case report. <i>Ment Health Clin</i>. 2019;9(5):315-317. doi:10.9740/mhc.2019.09.315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/31534873/pubmed" id="31534873" target="_blank">31534873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21601409">
<a name="21601409"></a>Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. <i>J Emerg Med</i>. 2012b;43(5):790-797. doi: 10.1016/j.jemermed.2011.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21601409/pubmed" id="21601409" target="_blank">21601409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28987309">
<a name="28987309"></a>Wilson MP, Nordstrom K, Hopper A, Porter A, Castillo EM, Vilke GM. Risperidone in the emergency setting is associated with more hypotension in elderly patients. <i>J Emerg Med</i>. 2017;53(5):735-739. doi: 10.1016/j.jemermed.2017.06.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28987309/pubmed" id="28987309" target="_blank">28987309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. <i>West J Emerg Med.</i> 2012a;13(1):26-34. doi: 10.5811/westjem.2011.9.6866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21508932">
<a name="21508932"></a>Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. <i>Neuropsychopharmacology</i>. 2011;36(8):1738-1746. doi:10.1038/npp.2011.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21508932/pubmed" id="21508932" target="_blank">21508932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29509183">
<a name="29509183"></a>Woon LS, Tee CK, Gan LLY, Deang KT, Chan LF. Olanzapine-induced and risperidone-induced leukopenia: a case of synergistic adverse reaction? <i>J Psychiatr Pract</i>. 2018;24(2):121-124. doi:10.1097/PRA.0000000000000292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29509183/pubmed" id="29509183" target="_blank">29509183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27627971">
<a name="27627971"></a>Yoshimura R, Hori H, Katsuki A, Atake K. Marked improvement of Meige syndrome in a Japanese male patient with schizophrenia after switching from risperidone to paliperidone: a case report. <i>J UOEH</i>. 2016;38(3):233-236. doi:10.7888/juoeh.38.233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27627971/pubmed" id="27627971" target="_blank">27627971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9868 Version 670.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
